{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:12Z","timestamp":1790790552797,"version":"4.1.0"},"reference-count":416,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02862-y","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:33:16Z","timestamp":1779424396000},"page":"1699-1742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE)"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4931","authenticated-orcid":false,"given":"Giovanna","family":"Muscogiuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Cignarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gambineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Giandalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualino","family":"Malandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Prodam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vignozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"1","key":"2862_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"issue":"11","key":"2862_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2862_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R et al (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20(1):46\u201362","journal-title":"Pituitary"},{"issue":"2","key":"2862_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N Moller","year":"2009","unstructured":"Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152\u2013177","journal-title":"Endocr Rev"},{"issue":"1","key":"2862_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/dmrr.919","volume":"25","author":"SN Rajpathak","year":"2009","unstructured":"Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R et al (2009) The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 25(1):3\u201312","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"2862_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-013-9904-3","volume":"44","author":"VE Chaves","year":"2013","unstructured":"Chaves VE, Junior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocrine 44(2):293\u2013302","journal-title":"Endocrine"},{"issue":"7","key":"2862_CR7","first-page":"594","volume":"8","author":"CM Szego","year":"1948","unstructured":"Szego CM, White A (1948) The influence of purified growth hormone on fasting metabolism. J Clin Endocrinol Metab 8(7):594","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2862_CR8","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1210\/jc.2002-020563","volume":"87","author":"TK Hansen","year":"2002","unstructured":"Hansen TK, Gravholt CH, H OR, Rasmussen MH, Christiansen JS, Jorgensen JO (2002) Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 87(10):4691\u20134698","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2862_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MOL.0000000000000297","volume":"27","author":"G Olivecrona","year":"2016","unstructured":"Olivecrona G (2016) Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol 27(3):233\u2013241","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"2862_CR10","doi-asserted-by":"publisher","first-page":"E1360","DOI":"10.1152\/ajpendo.00335.2001","volume":"282","author":"T Pratipanawatr","year":"2002","unstructured":"Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K et al (2002) Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab 282(6):E1360\u2013E1368","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"2862_CR11","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1210\/jc.2003-031682","volume":"89","author":"LM Scavo","year":"2004","unstructured":"Scavo LM, Karas M, Murray M, Leroith D (2004) Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab 89(7):3543\u20133553","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02642-0","author":"F Costanza","year":"2025","unstructured":"Costanza F, Basile C, Chiloiro S, Hessman E, Chantzichristos D, Pontecorvi A et al (2025) Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: A systematic review and meta-analysis. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-025-02642-0","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2862_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cen.14750","volume":"98","author":"J Dal","year":"2023","unstructured":"Dal J, Rosendal C, Karmisholt J, Feldt-Rasmussen U, Andersen MS, Klose M et al (2023) Sex difference in patients with controlled acromegaly-A multicentre survey. Clin Endocrinol (Oxf) 98(1):74\u201381","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2862_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000486001","volume":"49","author":"M Mercado","year":"2018","unstructured":"Mercado M, Ramirez-Renteria C (2018) Metabolic complications of acromegaly. Front Horm Res 49:20\u201328","journal-title":"Front Horm Res"},{"issue":"2","key":"2862_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0021-9150(00)00433-0","volume":"153","author":"JA Beentjes","year":"2000","unstructured":"Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP (2000) Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153(2):491\u2013498","journal-title":"Atherosclerosis"},{"issue":"3-4","key":"2862_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000371818","volume":"103","author":"NC Olarescu","year":"2016","unstructured":"Olarescu NC, Heck A, Godang K, Ueland T, Bollerslev J (2016) The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 103(3\u20134):197\u2013206","journal-title":"Neuroendocrinology"},{"issue":"9","key":"2862_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","volume":"20","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, Jorgensen JOL et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 20(9):541\u2013552","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2862_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","volume":"15","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF et al (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4):539\u2013551","journal-title":"Pituitary"},{"key":"2862_CR19","unstructured":"Feingold KR. (2000) The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth (MA)."},{"issue":"6","key":"2862_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0029-1211774","volume":"105","author":"J Wildbrett","year":"1997","unstructured":"Wildbrett J, Hanefeld M, Fucker K, Pinzer T, Bergmann S, Siegert G et al (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 105(6):331\u2013335","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2862_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256975","volume":"14","author":"M Romanisio","year":"2023","unstructured":"Romanisio M, Pitino R, Ferrero A, Pizzolitto F, Costelli S, Antoniotti V et al (2023) Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study. Front Endocrinol (Lausanne) 14:1256975","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2862_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2265.2012.04414.x","volume":"77","author":"L Boero","year":"2012","unstructured":"Boero L, Manavela M, Merono T, Maidana P, Gomez Rosso L, Brites F (2012) GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 77(4):579\u2013585","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2862_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/0026-0495(75)90129-8","volume":"24","author":"EA Nikkila","year":"1975","unstructured":"Nikkila EA, Pelkonen R (1975) Serum lipids in acromegaly. Metabolism 24(7):829\u2013838","journal-title":"Metabolism"},{"issue":"5","key":"2862_CR24","first-page":"513","volume":"64","author":"H Sumino","year":"2016","unstructured":"Sumino H, Murakami M (2016) [Causes and abnormal lipid laboratory values of secondary hyperlipidemia: endocrine disease]. Rinsho Byori 64(5):513\u2013517","journal-title":"Rinsho Byori"},{"issue":"3","key":"2862_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1046\/j.1365-2265.2000.01092.x","volume":"53","author":"GF Maldonado Castro","year":"2000","unstructured":"Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gomez-Coronado D, Balsa Barro JA, Varela C et al (2000) Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf) 53(3):313\u2013319","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2862_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0021-9150(99)00426-8","volume":"151","author":"M Arosio","year":"2000","unstructured":"Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E (2000) LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Atherosclerosis 151(2):551\u2013557 (Italian Multicenter Octreotide Study Group)","journal-title":"Atherosclerosis"},{"issue":"1","key":"2862_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0021-9150(96)06015-7","volume":"129","author":"KC Tan","year":"1997","unstructured":"Tan KC, Shiu SW, Janus ED, Lam KS (1997) LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 129(1):59\u201365","journal-title":"Atherosclerosis"},{"issue":"6","key":"2862_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7326\/0003-4819-130-6-199903160-00021","volume":"130","author":"P Maffei","year":"1999","unstructured":"Maffei P, Sicolo N, Plebani M (1999) Lipoprotein(a) in acromegaly. Ann Intern Med 130(6):537\u2013538","journal-title":"Ann Intern Med"},{"issue":"4","key":"2862_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4158\/EP.13.4.363","volume":"13","author":"L Vilar","year":"2007","unstructured":"Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363\u2013372","journal-title":"Endocr Pract"},{"issue":"8","key":"2862_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-2007-1003343","volume":"24","author":"R Cohen","year":"1992","unstructured":"Cohen R, Chanson P, Bruckert E, Timsit J, Legrand A, Harris AG et al (1992) Effects of octreotide on lipid metabolism in acromegaly. Horm Metab Res 24(8):397\u2013400","journal-title":"Horm Metab Res"},{"issue":"1","key":"2862_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1055\/a-1717-9332","volume":"54","author":"XQ Shao","year":"2022","unstructured":"Shao XQ, Chen ZY, Wang M, Yang YP, Yu YF, Liu WJ et al (2022) Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases. Horm Metab Res 54(1):25\u201332","journal-title":"Horm Metab Res"},{"issue":"3","key":"2862_CR32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/clinem\/dgz244","volume":"105","author":"M Wang","year":"2020","unstructured":"Wang M, Guo S, He M, Shao X, Feng L, Yu Y et al (2020) High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly. J Clin Endocrinol Metab 105(3):34","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2862_CR33","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2017-01210","volume":"102","author":"MA Bredella","year":"2017","unstructured":"Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW et al (2017) Body composition and ectopic lipid changes with biochemical control of acromegaly. J Clin Endocrinol Metab 102(11):4218\u20134225","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2862_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1172\/jci.insight.134638","volume":"5","author":"P Fellinger","year":"2020","unstructured":"Fellinger P, Wolf P, Pfleger L, Krumpolec P, Krssak M, Klavins K et al (2020) Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight. 5(5):34","journal-title":"JCI Insight."},{"issue":"4","key":"2862_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020) A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab 105(4):45","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2862_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","volume":"26","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML (2023) Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4):319\u2013332","journal-title":"Pituitary"},{"issue":"13","key":"2862_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/ijms241310974","volume":"24","author":"A Jawiarczyk-Przybylowska","year":"2023","unstructured":"Jawiarczyk-Przybylowska A, Kuliczkowska-Plaksej J, Kolackov K, Zembska A, Halupczok-Zyla J, Rolla M et al (2023) FTO Gene Polymorphisms and Their Roles in Acromegaly. Int J Mol Sci 24(13):44","journal-title":"Int J Mol Sci"},{"key":"2862_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00120","volume":"10","author":"AM Ramos-Levi","year":"2019","unstructured":"Ramos-Levi AM, Marazuela M (2019) Bringing cardiovascular comorbidities in acromegaly to an update. How should we diagnose and manage them? Front Endocrinol (Lausanne) 10:120","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2862_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"1","key":"2862_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M et al (2022) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 29(1):5\u2013115","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"2862_CR41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/cen.13285","volume":"86","author":"PJ Caron","year":"2017","unstructured":"Caron PJ, Petersenn S, Houchard A, Sert C, Bevan JS, Group PS (2017) Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf) 86(4):541\u2013551","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2862_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf) 79(6):845\u2013852","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2862_CR43","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","volume":"87","author":"G Sesmilo","year":"2002","unstructured":"Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V et al (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692\u20131699","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2265.2005.02273.x","volume":"62","author":"M Mishra","year":"2005","unstructured":"Mishra M, Durrington P, Mackness M, Siddals KW, Kaushal K, Davies R et al (2005) The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) 62(6):650\u2013655","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2862_CR45","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","volume":"30","author":"L Persson","year":"2010","unstructured":"Persson L, Cao G, Stahle L, Sjoberg BG, Troutt JS, Konrad RJ et al (2010) Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 30(12):2666\u20132672","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2862_CR46","doi-asserted-by":"publisher","first-page":"101667","DOI":"10.1016\/j.beem.2022.101667","volume":"37","author":"CB Newman","year":"2023","unstructured":"Newman CB (2023) Effects of endocrine disorders on lipids and lipoproteins. Best Pract Res Clin Endocrinol Metab 37(3):101667","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2862_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.clnesp.2025.03.035","volume":"67","author":"NN Hupalowski","year":"2025","unstructured":"Hupalowski NN, Sanches Rocha CP, Castaldo VF, Boguszewski CL, Cochenski Borba VZ (2025) Impact of nutrient intake on bone mineral density and bone quality in patients with acromegaly. Clin Nutr ESPEN 67:398\u2013403","journal-title":"Clin Nutr ESPEN"},{"issue":"1 Suppl 1","key":"2862_CR48","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice C.","year":"2025","unstructured":"American Diabetes Association Professional Practice C. (2025) 10. Cardiovascular disease and risk management: Standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S207\u2013S238","journal-title":"Diabetes Care"},{"issue":"6","key":"2862_CR49","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-023-05894-8","volume":"66","author":"Diabetes, Nutrition Study Group of the European Association for the Study of D","year":"2023","unstructured":"Diabetes, Nutrition Study Group of the European Association for the Study of D (2023) Evidence-based European recommendations for the dietary management of diabetes. Diabetologia 66(6):965\u2013985","journal-title":"Diabetologia"},{"issue":"39","key":"2862_CR50","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140","journal-title":"Eur Heart J"},{"issue":"10338","key":"2862_CR51","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","volume":"399","author":"J Delgado-Lista","year":"2022","unstructured":"Delgado-Lista J, Alcala-Diaz JF, Torres-Pena JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A et al (2022) Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399(10338):1876\u20131885","journal-title":"Lancet"},{"issue":"25","key":"2862_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F et al (2018) Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 378(25):e34","journal-title":"N Engl J Med"},{"issue":"5","key":"2862_CR53","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/nu17050862","volume":"17","author":"A Muszalska","year":"2025","unstructured":"Muszalska A, Wiecanowska J, Michalowska J, Pastusiak-Zgolinska KM, Polok I, Lompies K et al (2025) The Role of the Planetary Diet in Managing Metabolic Syndrome and Cardiovascular Disease: A Narrative Review. Nutrients 17(5):344","journal-title":"Nutrients"},{"issue":"5","key":"2862_CR54","first-page":"34","volume":"5","author":"A Bensaaud","year":"2025","unstructured":"Bensaaud A, Seery S, Gibson I, Jones J, Flaherty G, McEvoy JW et al (2025) Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases. Cochrane Database Syst Rev 5(5):34","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2862_CR55","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/BF03345660","volume":"31","author":"S Grottoli","year":"2008","unstructured":"Grottoli S, Gasco V, Mainolfi A, Beccuti G, Corneli G, Aimaretti G et al (2008) Growth hormone\/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly. J Endocrinol Invest 31(12):1103\u20131109","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2862_CR56","first-page":"812","volume":"75","author":"PJ Ho","year":"1992","unstructured":"Ho PJ, Friberg RD, Barkan AL (1992) Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab 75(3):812\u2013819","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2862_CR57","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMc1915808","volume":"382","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Berk KAC, El-Sayed N, Neggers S, van der Lely AJ (2020) Eucaloric very-low-carbohydrate ketogenic diet in acromegaly treatment. N Engl J Med 382(22):2161\u20132162","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1530\/eje.1.02179","volume":"155","author":"R Abs","year":"2006","unstructured":"Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI et al (2006) Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol 155(1):79\u201390","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2862_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101821","volume":"37","author":"M Hepprich","year":"2023","unstructured":"Hepprich M, Ebrahimi F, Christ E (2023) Dyslipidaemia and growth hormone deficiency - A comprehensive review. Best Pract Res Clin Endocrinol Metab 37(6):101821","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2862_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00032","volume":"2","author":"A Vijayakumar","year":"2011","unstructured":"Vijayakumar A, Yakar S, Leroith D (2011) The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne) 2:32","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"26","key":"2862_CR61","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","volume":"321","author":"F Salomon","year":"1989","unstructured":"Salomon F, Cuneo RC, Hesp R, Sonksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321(26):1797\u20131803","journal-title":"N Engl J Med"},{"issue":"3","key":"2862_CR62","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00496089","volume":"133","author":"M Zachmann","year":"1980","unstructured":"Zachmann M, Fernandez F, Tassinari D, Thakker R, Prader A (1980) Anthropometric measurements in patients with growth hormone deficiency before treatment with human growth hormone. Eur J Pediatr 133(3):277\u2013282","journal-title":"Eur J Pediatr"},{"issue":"9","key":"2862_CR63","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1172\/JCI119398","volume":"99","author":"M Rudling","year":"1997","unstructured":"Rudling M, Parini P, Angelin B (1997) Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J Clin Invest 99(9):2239\u20132245","journal-title":"J Clin Invest"},{"issue":"9","key":"2862_CR64","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40618-016-0475-z","volume":"39","author":"A Ciresi","year":"2016","unstructured":"Ciresi A, Pizzolanti G, Leotta M, Guarnotta V, Teresi G, Giordano C (2016) Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children. J Endocrinol Invest 39(9):1023\u20131030","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2862_CR65","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1210\/jcem.86.12.8087","volume":"86","author":"G Sesmilo","year":"2001","unstructured":"Sesmilo G, Miller KK, Hayden D, Klibanski A (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86(12):5774\u20135781","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2862_CR66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1530\/EJE-12-0263","volume":"167","author":"EJ Barbosa","year":"2012","unstructured":"Barbosa EJ, Glad CA, Nilsson AG, Filipsson Nystrom H, Gotherstrom G, Svensson PA et al (2012) Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. Eur J Endocrinol 167(3):353\u2013362","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2862_CR67","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1210\/jc.2003-030840","volume":"89","author":"P Maison","year":"2004","unstructured":"Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P et al (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized. Placebo-Controlled Trials J Clin Endocrinol Metab 89(5):2192\u20132199","journal-title":"Placebo-Controlled Trials J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2265.2001.01320.x","volume":"55","author":"TA Abdu","year":"2001","unstructured":"Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 55(2):209\u2013216","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2862_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1210\/edrv-16-1-63","volume":"16","author":"H de Boer","year":"1995","unstructured":"de Boer H, Blok GJ, Van der Veen EA (1995) Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16(1):63\u201386","journal-title":"Endocr Rev"},{"issue":"1","key":"2862_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.beem.2017.03.005","volume":"31","author":"C Di Somma","year":"2017","unstructured":"Di Somma C, Scarano E, Savastano S, Savanelli MC, Pivonello R, Colao A (2017) Cardiovascular alterations in adult GH deficiency. Best Pract Res Clin Endocrinol Metab 31(1):25\u201334","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR71","first-page":"227","volume":"90","author":"G Gacs","year":"1987","unstructured":"Gacs G, Romics L (1987) Effect of growth hormone on serum lipoproteins in growth hormone deficiency. Exp Clin Endocrinol 90(2):227\u2013231","journal-title":"Exp Clin Endocrinol"},{"issue":"12","key":"2862_CR72","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/0026-0495(94)90001-9","volume":"43","author":"GB Schaefer","year":"1994","unstructured":"Schaefer GB, Greger NG, Fesmire JD, Blackett PR, Wilson DP, Frindik JP (1994) Lipids and apolipoproteins in growth hormone-deficient children during treatment. Metabolism 43(12):1457\u20131461","journal-title":"Metabolism"},{"issue":"1","key":"2862_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0026-0495(84)90162-8","volume":"33","author":"RJ Winter","year":"1984","unstructured":"Winter RJ, Green OC (1984) Effect of thyroxine and growth hormone on the hypercholesterolemia of growth hormone deficiency. Metabolism 33(1):54\u201357","journal-title":"Metabolism"},{"issue":"11","key":"2862_CR74","first-page":"3890","volume":"83","author":"R Kuromaru","year":"1998","unstructured":"Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S, Hara T (1998) Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects. J Clin Endocrinol Metab 83(11):3890\u20133896","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2862_CR75","first-page":"3786","volume":"85","author":"T Sas","year":"2000","unstructured":"Sas T, Mulder P, Hokken-Koelega A (2000) Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 85(10):3786\u20133792","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2862_CR76","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/0026-0495(79)90138-0","volume":"28","author":"RJ Winter","year":"1979","unstructured":"Winter RJ, Thompson RG, Green OC (1979) Serum cholesterol and triglycerides in children with growth hormone deficiency. Metabolism 28(12):1244\u20131249","journal-title":"Metabolism"},{"issue":"6","key":"2862_CR77","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ghir.2015.08.005","volume":"25","author":"C Binay","year":"2015","unstructured":"Binay C, Simsek E, Yildirim A, Kosger P, Demiral M, Kilic Z (2015) Growth hormone and the risk of atherosclerosis in growth hormone-deficient children. Growth Horm IGF Res 25(6):294\u2013297","journal-title":"Growth Horm IGF Res"},{"issue":"9","key":"2862_CR78","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1210\/jc.2008-2639","volume":"94","author":"D Capalbo","year":"2009","unstructured":"Capalbo D, Lo Vecchio A, Farina V, Spinelli L, Palladino A, Tiano C et al (2009) Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. J Clin Endocrinol Metab 94(9):3347\u20133355","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR79","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000444143","volume":"85","author":"C De Leonibus","year":"2016","unstructured":"De Leonibus C, De Marco S, Stevens A, Clayton P, Chiarelli F, Mohn A (2016) Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease. Horm Res Paediatr 85(6):363\u2013371","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2862_CR80","first-page":"209","volume":"2","author":"R Lanes","year":"2004","unstructured":"Lanes R (2004) Metabolic abnormalities in growth hormone deficiency. Pediatr Endocrinol Rev 2(2):209\u2013215","journal-title":"Pediatr Endocrinol Rev"},{"issue":"5","key":"2862_CR81","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1210\/jcem.85.5.6598","volume":"85","author":"N Vahl","year":"2000","unstructured":"Vahl N, Juul A, Jorgensen JO, Orskov H, Skakkebaek NE, Christiansen JS (2000) Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 85(5):1874\u20131881","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2862_CR82","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1210\/jc.2003-031588","volume":"89","author":"PV Carroll","year":"2004","unstructured":"Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB et al (2004) Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 89(8):3890\u20133895","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2862_CR83","first-page":"4516","volume":"84","author":"G Johannsson","year":"1999","unstructured":"Johannsson G, Albertsson-Wikland K, Bengtsson BA (1999) Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 84(12):4516\u20134524","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2862_CR84","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1210\/jc.2003-030392","volume":"88","author":"M Tauber","year":"2003","unstructured":"Tauber M, Jouret B, Cartault A, Lounis N, Gayrard M, Marcouyeux C et al (2003) Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. J Clin Endocrinol Metab 88(11):5101\u20135106","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR85","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1210\/jc.2009-2013","volume":"95","author":"M Koltowska-Haggstrom","year":"2010","unstructured":"Koltowska-Haggstrom M, Geffner ME, Jonsson P, Monson JP, Abs R, Hana V et al (2010) Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab 95(6):2646\u20132654","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3803\/EnM.2021.1384","volume":"37","author":"YJ Lee","year":"2022","unstructured":"Lee YJ, Choi Y, Yoo HW, Lee YA, Shin CH, Choi HS et al (2022) Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency. Endocrinol Metab (Seoul) 37(2):359\u2013368","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"7","key":"2862_CR87","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1515\/jpem-2017-0098","volume":"30","author":"J Rothermel","year":"2017","unstructured":"Rothermel J, Lass N, Bosse C, Reinehr T (2017) Impact of discontinuation of growth hormone treatment on lipids and weight status in adolescents. J Pediatr Endocrinol Metab 30(7):749\u2013757","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2862_CR88","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jcem.82.5.3951","volume":"82","author":"B Capaldo","year":"1997","unstructured":"Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F et al (1997) Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 82(5):1378\u20131381","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2862_CR89","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1210\/jcem.86.3.7268","volume":"86","author":"R Lanes","year":"2001","unstructured":"Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R (2001) Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 86(3):1061\u20131065","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2862_CR90","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/0026-0495(93)90145-E","volume":"42","author":"RC Cuneo","year":"1993","unstructured":"Cuneo RC, Salomon F, Watts GF, Hesp R, Sonksen PH (1993) Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42(12):1519\u20131523","journal-title":"Metabolism"},{"issue":"12","key":"2862_CR91","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1507\/endocrj.EJ15-0337","volume":"62","author":"L Giovannini","year":"2015","unstructured":"Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G (2015) Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J 62(12):1037\u20131048","journal-title":"Endocr J"},{"issue":"7","key":"2862_CR92","first-page":"2448","volume":"81","author":"D O\u2019Neal","year":"1996","unstructured":"O\u2019Neal D, Hew FL, Sikaris K, Ward G, Alford F, Best JD (1996) Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy. J Clin Endocrinol Metab 81(7):2448\u20132454","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2862_CR93","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1210\/jcem.84.4.5605","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C et al (1999) The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 84(4):1277\u20131282","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR94","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1530\/eje.1.01967","volume":"153","author":"G Corneli","year":"2005","unstructured":"Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG et al (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153(2):257\u2013264","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2862_CR95","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s40618-023-02081-9","volume":"46","author":"V Gasco","year":"2023","unstructured":"Gasco V, Cuboni D, Varaldo E, Bioletto F, Berton AM, Bona C et al (2023) GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency? J Endocrinol Invest 46(10):2175\u20132183","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2862_CR96","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40618-019-01100-y","volume":"43","author":"V Gasco","year":"2020","unstructured":"Gasco V, Roncoroni L, Zavattaro M, Bona C, Berton A, Ghigo E et al (2020) Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study. J Endocrinol Invest 43(2):197\u2013207","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2862_CR97","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0022-2275(20)32065-4","volume":"41","author":"CJ Packard","year":"2000","unstructured":"Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G et al (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41(2):305\u2013318","journal-title":"J Lipid Res"},{"issue":"2","key":"2862_CR98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2005.08.013","volume":"17","author":"M Rizzo","year":"2006","unstructured":"Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular prevention. Eur J Intern Med 17(2):77\u201380","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2862_CR99","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/EJE-06-0652","volume":"156","author":"M Rizzo","year":"2007","unstructured":"Rizzo M, Trepp R, Berneis K, Christ ER (2007) Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 156(3):361\u2013367","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2862_CR100","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ghir.2007.10.003","volume":"18","author":"M Rizzo","year":"2008","unstructured":"Rizzo M, Trepp R, Berneis K, Christ ER (2008) Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. Growth Horm IGF Res 18(3):264\u2013266","journal-title":"Growth Horm IGF Res"},{"issue":"11","key":"2862_CR101","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/GL-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM et al (2019) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocr Pract 25(11):1191\u20131232","journal-title":"Endocr Pract"},{"issue":"6","key":"2862_CR102","first-page":"673","volume":"64","author":"G Rissetti","year":"2021","unstructured":"Rissetti G, Zeni D, Ongaratti BR, Pereira-Lima JFS, Rech C, da Costa Oliveira M (2021) Lipid profile and response to statin therapy in patients with hypopituitarism. Arch Endocrinol Metab 64(6):673\u2013678","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"2862_CR103","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1210\/endo.136.9.7649083","volume":"136","author":"P Parini","year":"1995","unstructured":"Parini P, Angelin B, Lobie PE, Norstedt G, Rudling M (1995) Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells. Endocrinology 136(9):3767\u20133773","journal-title":"Endocrinology"},{"issue":"3","key":"2862_CR104","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11102-014-0571-z","volume":"18","author":"CB Newman","year":"2015","unstructured":"Newman CB, Carmichael JD, Kleinberg DL (2015) Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary 18(3):297\u2013305","journal-title":"Pituitary"},{"issue":"4","key":"2862_CR105","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2265.2000.01108.x","volume":"53","author":"D Florakis","year":"2000","unstructured":"Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL et al (2000) Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 53(4):453\u2013459","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2862_CR106","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2265.2007.02935.x","volume":"67","author":"JP Monson","year":"2007","unstructured":"Monson JP, Jonsson P, Koltowska-Haggstrom M, Kourides I (2007) Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 67(4):623\u2013628","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2862_CR107","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/01.ATV.0000110657.67317.90","volume":"24","author":"S Lind","year":"2004","unstructured":"Lind S, Rudling M, Ericsson S, Olivecrona H, Eriksson M, Borgstrom B et al (2004) Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 24(2):349\u2013356","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"2862_CR108","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/eurheartj\/ehv595","volume":"37","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D (2016) Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J 37(13):1079\u20131081","journal-title":"Eur Heart J"},{"issue":"3","key":"2862_CR109","first-page":"472","volume":"34","author":"TJ Moore","year":"1999","unstructured":"Moore TJ, Vollmer WM, Appel LJ, Sacks FM, Svetkey LP, Vogt TM et al (1999) Effect of dietary patterns on ambulatory blood pressure\u202f: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group Hypertension 34(3):472\u2013477","journal-title":"DASH Collaborative Research Group Hypertension"},{"issue":"25","key":"2862_CR110","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMc1806491","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F et al (2018) Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90. N Engl J Med 378(25):2441\u20132442","journal-title":"N Engl J Med"},{"issue":"6","key":"2862_CR111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cells10061376","volume":"10","author":"M Caputo","year":"2021","unstructured":"Caputo M, Pigni S, Agosti E, Daffara T, Ferrero A, Filigheddu N et al (2021) Regulation of GH and GH Signaling by Nutrients. Cells 10(6):34","journal-title":"Cells"},{"key":"2862_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092228","author":"G Muscogiuri","year":"2019","unstructured":"Muscogiuri G, Barrea L, Laudisio D, Di Somma C, Pugliese G, Salzano C et al (2019) Somatotropic axis and obesity: is there any role for the Mediterranean diet? Nutrients. https:\/\/doi.org\/10.3390\/nu11092228","journal-title":"Nutrients"},{"issue":"1","key":"2862_CR113","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41575-024-00991-4","volume":"22","author":"RA Sinha","year":"2025","unstructured":"Sinha RA, Bruinstroop E, Yen PM (2025) Actions of thyroid hormones and thyromimetics on the liver. Nat Rev Gastroenterol Hepatol 22(1):9\u201322","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2862_CR114","first-page":"607","volume":"35","author":"CL Chng","year":"2025","unstructured":"Chng CL, Goh GBB, Yen PM (2025) Metabolic and functional cross talk between the thyroid and liver. Thyroid 35(6):607\u2013623","journal-title":"Thyroid"},{"issue":"8","key":"2862_CR115","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/endocr\/bqab059","volume":"162","author":"SC Russo","year":"2021","unstructured":"Russo SC, Salas-Lucia F, Bianco AC (2021) Deiodinases and the Metabolic Code for Thyroid Hormone Action. Endocrinology 162(8):34","journal-title":"Endocrinology"},{"key":"2862_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040744","author":"F Damiano","year":"2017","unstructured":"Damiano F, Rochira A, Gnoni A, Siculella L (2017) Action of thyroid hormones, T3 and T2, on hepatic fatty acids: differences in metabolic effects and molecular mechanisms. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18040744","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2862_CR117","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1210\/jc.2018-02302","volume":"104","author":"B Biondi","year":"2019","unstructured":"Biondi B (2019) Persistent dyslipidemia in patients with hypothyroidism: a good marker for personalized replacement therapy? J Clin Endocrinol Metab 104(2):624\u2013627","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR118","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1530\/EC-21-0002","volume":"11","author":"H Liu","year":"2022","unstructured":"Liu H, Peng D (2022) Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocr Connect 11(2):34","journal-title":"Endocr Connect"},{"issue":"4","key":"2862_CR119","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbrc.2013.09.116","volume":"440","author":"CS Yap","year":"2013","unstructured":"Yap CS, Sinha RA, Ota S, Katsuki M, Yen PM (2013) Thyroid hormone negatively regulates CDX2 and SOAT2 mRNA expression via induction of miRNA-181d in hepatic cells. Biochem Biophys Res Commun 440(4):635\u2013639","journal-title":"Biochem Biophys Res Commun"},{"key":"2862_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312797","author":"M Mavromati","year":"2021","unstructured":"Mavromati M, Jornayvaz FR (2021) Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312797","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2862_CR121","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ (2025) Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov 24(3):171\u2013189","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2862_CR122","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12944-025-02474-0","volume":"24","author":"S Pu","year":"2025","unstructured":"Pu S, Zhao B, Jiang Y, Cui X (2025) Hypothyroidism\/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment. Lipids Health Dis 24(1):75","journal-title":"Lipids Health Dis"},{"key":"2862_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914605","author":"P Vidal-Cevallos","year":"2023","unstructured":"Vidal-Cevallos P, Murua-Beltran Gall S, Uribe M, Chavez-Tapia NC (2023) Understanding the relationship between nonalcoholic fatty liver disease and thyroid disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241914605","journal-title":"Int J Mol Sci"},{"key":"2862_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00511","volume":"9","author":"LH Duntas","year":"2018","unstructured":"Duntas LH, Brenta G (2018) A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol (Lausanne) 9:511","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2862_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40842-024-00187-4","volume":"10","author":"B Basil","year":"2024","unstructured":"Basil B, Myke-Mbata BK, Eze OE, Akubue AU (2024) From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol 10(1):39","journal-title":"Clin Diabetes Endocrinol"},{"issue":"4","key":"2862_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299507","volume":"19","author":"M Gurun","year":"2024","unstructured":"Gurun M, Brennan P, Handjiev S, Khatib A, Leith D, Dillon JF et al (2024) Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS ONE 19(4):e0299507","journal-title":"PLoS ONE"},{"key":"2862_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-016-0021-0","volume":"2","author":"S Khatiwada","year":"2016","unstructured":"Khatiwada S, Sah SK, Kc R, Baral N, Lamsal M (2016) Thyroid dysfunction in metabolic syndrome patients and its relationship with components of metabolic syndrome. Clin Diabetes Endocrinol 2:3","journal-title":"Clin Diabetes Endocrinol"},{"key":"2862_CR128","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820917869","volume":"11","author":"P Teixeira","year":"2020","unstructured":"Teixeira P, Dos Santos PB, Pazos-Moura CC (2020) The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab 11:2042018820917869","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"2862_CR129","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/er.2018-00163","volume":"40","author":"B Biondi","year":"2019","unstructured":"Biondi B, Kahaly GJ, Robertson RP (2019) Thyroid dysfunction and Diabetes Mellitus: Two closely associated disorders. Endocr Rev 40(3):789\u2013824","journal-title":"Endocr Rev"},{"issue":"7","key":"2862_CR130","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1464-5491.1995.tb00553.x","volume":"12","author":"P Perros","year":"1995","unstructured":"Perros P, McCrimmon RJ, Shaw G, Frier BM (1995) Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 12(7):622\u2013627","journal-title":"Diabet Med"},{"issue":"1","key":"2862_CR131","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/thy.2016.0171","volume":"27","author":"JE Jun","year":"2017","unstructured":"Jun JE, Jee JH, Bae JC, Jin SM, Hur KY, Lee MK et al (2017) Association between changes in thyroid hormones and incident Type 2 Diabetes: A seven-year longitudinal study. Thyroid 27(1):29\u201338","journal-title":"Thyroid"},{"issue":"1","key":"2862_CR132","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-022-00357-7","volume":"8","author":"L Chaker","year":"2022","unstructured":"Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP (2022) Hypothyroidism. Nat Rev Dis Primers 8(1):30","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2862_CR133","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-023-03420-9","volume":"84","author":"J Jonklaas","year":"2024","unstructured":"Jonklaas J (2024) Hypothyroidism, lipids, and lipidomics. Endocrine 84(2):293\u2013300","journal-title":"Endocrine"},{"issue":"9","key":"2862_CR134","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1089\/thy.2015.0410","volume":"26","author":"D Tiller","year":"2016","unstructured":"Tiller D, Ittermann T, Greiser KH, Meisinger C, Agger C, Hofman A et al (2016) Association of serum thyrotropin with anthropometric markers of obesity in the general population. Thyroid 26(9):1205\u20131214","journal-title":"Thyroid"},{"issue":"4","key":"2862_CR135","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.trsl.2007.12.006","volume":"151","author":"F Teixeira Pde","year":"2008","unstructured":"Teixeira Pde F, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Buescu A et al (2008) Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res 151(4):224\u2013231","journal-title":"Transl Res"},{"key":"2862_CR136","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.12659\/MSM.891163","volume":"20","author":"XL Liu","year":"2014","unstructured":"Liu XL, He S, Zhang SF, Wang J, Sun XF, Gong CM et al (2014) Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Med Sci Monit 20:1432\u20131441","journal-title":"Med Sci Monit"},{"issue":"2","key":"2862_CR137","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1210\/jc.2011-2532","volume":"97","author":"EN Pearce","year":"2012","unstructured":"Pearce EN (2012) Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 97(2):326\u2013333","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2862_CR138","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1055\/s-2008-1077051","volume":"55","author":"J Liu","year":"2023","unstructured":"Liu J, Chen Y, Ren B, He Y, Li F, Wang L et al (2023) Alteration of lipid profile between subclinical hypothyroidism and well-matched controls: a meta-analysis. Horm Metab Res 55(7):479\u2013486","journal-title":"Horm Metab Res"},{"issue":"3","key":"2862_CR139","first-page":"159","volume":"55","author":"MS Saric","year":"2017","unstructured":"Saric MS, Jurasic MJ, Sovic S, Kranjcec B, Glivetic T, Demarin V (2017) Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C). Rom J Intern Med 55(3):159\u2013166","journal-title":"Rom J Intern Med"},{"issue":"4","key":"2862_CR140","first-page":"428","volume":"46","author":"Y Treister-Goltzman","year":"2021","unstructured":"Treister-Goltzman Y, Yarza S, Peleg R (2021) Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis. Minerva Endocrinol (Torino) 46(4):428\u2013440","journal-title":"Minerva Endocrinol (Torino)"},{"issue":"240","key":"2862_CR141","first-page":"783","volume":"59","author":"P Khatri","year":"2021","unstructured":"Khatri P, Neupane A, Banjade A, Sapkota S, Kharel S, Chhetri A et al (2021) Lipid Profile Abnormalities in Newly Diagnosed Primary Hypothyroidism in a Tertiary Care Centre of Western Nepal: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 59(240):783\u2013786","journal-title":"JNMA J Nepal Med Assoc"},{"issue":"1","key":"2862_CR142","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/clinem\/dgac555","volume":"108","author":"F Shao","year":"2022","unstructured":"Shao F, Li R, Guo Q, Qin R, Su W, Yin H et al (2022) Plasma Metabolomics Reveals Systemic Metabolic Alterations of Subclinical and Clinical Hypothyroidism. J Clin Endocrinol Metab 108(1):13\u201325","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR143","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jacl.2017.08.015","volume":"11","author":"KY Jung","year":"2017","unstructured":"Jung KY, Ahn HY, Han SK, Park YJ, Cho BY, Moon MK (2017) Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function. J Clin Lipidol 11(6):1347\u20131353","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2862_CR144","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/thy.2018.0190","volume":"29","author":"GA Sigal","year":"2019","unstructured":"Sigal GA, Tavoni TM, Silva BMO, Kalil Filho R, Brandao LG, Maranhao RC (2019) Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer. Thyroid 29(1):53\u201358","journal-title":"Thyroid"},{"issue":"5","key":"2862_CR145","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1210\/jcem.83.5.4759","volume":"83","author":"T Diekman","year":"1998","unstructured":"Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM (1998) Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 83(5):1752\u20131755","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2862_CR146","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/105072502320908349","volume":"12","author":"LH Duntas","year":"2002","unstructured":"Duntas LH, Mantzou E, Koutras DA (2002) Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 12(11):1003\u20131007","journal-title":"Thyroid"},{"issue":"9","key":"2862_CR147","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/thy.2000.10.803","volume":"10","author":"T Tzotzas","year":"2000","unstructured":"Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M (2000) Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 10(9):803\u2013808","journal-title":"Thyroid"},{"key":"2862_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/nu17040659","author":"M Kalwick","year":"2025","unstructured":"Kalwick M, Roth M (2025) A comprehensive review of the genetics of dyslipidemias and risk of atherosclerotic cardiovascular disease. Nutrients. https:\/\/doi.org\/10.3390\/nu17040659","journal-title":"Nutrients"},{"key":"2862_CR149","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13559","author":"L Chaker","year":"2025","unstructured":"Chaker L, Papaleontiou M (2025) Hypothyroidism: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.13559","journal-title":"JAMA"},{"issue":"12","key":"2862_CR150","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS et al (2014) Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12):1670\u20131751","journal-title":"Thyroid"},{"key":"2862_CR151","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa672","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Cortes T, Genere N, Hamidi O, Jasim S, Newman CB et al (2020) Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa672","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2862_CR152","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1530\/ETJ-25-0123","volume":"14","author":"M Centanni","year":"2025","unstructured":"Centanni M, Duntas L, Feldt-Rasmussen U, Koehrle J, Peeters RP, Razvi S et al (2025) ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. Eur Thyroid J. 14(4):34","journal-title":"Eur Thyroid J."},{"issue":"1","key":"2862_CR153","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2796.2006.01652.x","volume":"260","author":"A Iqbal","year":"2006","unstructured":"Iqbal A, Jorde R, Figenschau Y (2006) Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. J Intern Med 260(1):53\u201361","journal-title":"J Intern Med"},{"issue":"10","key":"2862_CR154","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1210\/jcem.86.10.7973","volume":"86","author":"C Meier","year":"2001","unstructured":"Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR et al (2001) TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86(10):4860\u20134866","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2862_CR155","first-page":"4533","volume":"103","author":"EA McAninch","year":"2018","unstructured":"McAninch EA, Rajan KB, Miller CH, Bianco AC (2018) Systemic Thyroid Hormone Status During Levothyroxine Therapy In Hypothyroidism: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 103(12):4533\u20134542","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2862_CR156","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1210\/jc.2011-1329","volume":"96","author":"FS Celi","year":"2011","unstructured":"Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V et al (2011) Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 96(11):3466\u20133474","journal-title":"J Clin Endocrinol Metab"},{"issue":"3 Suppl","key":"2862_CR157","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Associations Muscle Safety Expert P (2014) An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8(3 Suppl):S58-71","journal-title":"J Clin Lipidol"},{"issue":"10","key":"2862_CR158","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1001\/jama.1969.03160100047012","volume":"208","author":"RC Northcutt","year":"1969","unstructured":"Northcutt RC, Stiel JN, Hollifield JW, Stant EG Jr (1969) The influence of cholestyramine on thyroxine absorption. JAMA 208(10):1857\u20131861","journal-title":"JAMA"},{"issue":"19","key":"2862_CR159","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJM198911093211914","volume":"321","author":"DM Demke","year":"1989","unstructured":"Demke DM (1989) Drug interaction between thyroxine and lovastatin. N Engl J Med 321(19):1341\u20131342","journal-title":"N Engl J Med"},{"issue":"2","key":"2862_CR160","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4274\/jcrpe.3719","volume":"9","author":"E Unal","year":"2017","unstructured":"Unal E, Akin A, Yildirim R, Demir V, Yildiz I, Haspolat YK (2017) Association of subclinical hypothyroidism with dyslipidemia and increased carotid intima-media thickness in children. J Clin Res Pediatr Endocrinol 9(2):144\u2013149","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"9","key":"2862_CR161","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3945\/jn.115.213439","volume":"145","author":"I Herter-Aeberli","year":"2015","unstructured":"Herter-Aeberli I, Cherkaoui M, El Ansari N, Rohner R, Stinca S, Chabaa L et al (2015) Iodine Supplementation Decreases Hypercholesterolemia in Iodine-Deficient, Overweight Women: A Randomized Controlled Trial. J Nutr 145(9):2067\u20132075","journal-title":"J Nutr"},{"issue":"3","key":"2862_CR162","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/nu8030171","volume":"8","author":"KW Lee","year":"2016","unstructured":"Lee KW, Shin D, Song WO (2016) Low urinary Iodine concentrations associated with dyslipidemia in US adults. Nutrients 8(3):171","journal-title":"Nutrients"},{"issue":"1","key":"2862_CR163","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6065\/apem.2014.19.1.8","volume":"19","author":"HR Chung","year":"2014","unstructured":"Chung HR (2014) Iodine and thyroid function. Ann Pediatr Endocrinol Metab 19(1):8\u201312","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"3","key":"2862_CR164","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/thy.2023.0556","volume":"34","author":"VV Huwiler","year":"2024","unstructured":"Huwiler VV, Maissen-Abgottspon S, Stanga Z, Muhlebach S, Trepp R, Bally L et al (2024) Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid 34(3):295\u2013313","journal-title":"Thyroid"},{"key":"2862_CR165","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7478523","volume":"2017","author":"N Wang","year":"2017","unstructured":"Wang N, Tan HY, Li S, Xu Y, Guo W, Feng Y (2017) Supplementation of micronutrient Selenium in metabolic diseases: its role as an antioxidant. Oxid Med Cell Longev 2017:7478523","journal-title":"Oxid Med Cell Longev"},{"key":"2862_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-015-0023-4","volume":"12","author":"P Ranasinghe","year":"2015","unstructured":"Ranasinghe P, Wathurapatha WS, Ishara MH, Jayawardana R, Galappatthy P, Katulanda P et al (2015) Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis. Nutr Metab (Lond) 12:26","journal-title":"Nutr Metab (Lond)"},{"issue":"2","key":"2862_CR167","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000103324","volume":"51","author":"C Maxwell","year":"2007","unstructured":"Maxwell C, Volpe SL (2007) Effect of zinc supplementation on thyroid hormone function. A case study of two college females. Ann Nutr Metab 51(2):188\u2013194","journal-title":"Ann Nutr Metab"},{"issue":"19","key":"2862_CR168","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/nu14194130","volume":"14","author":"G Bellastella","year":"2022","unstructured":"Bellastella G, Scappaticcio L, Caiazzo F, Tomasuolo M, Carotenuto R, Caputo M et al (2022) Mediterranean Diet and Thyroid: An Interesting Alliance. Nutrients 14(19):34","journal-title":"Nutrients"},{"issue":"11","key":"2862_CR169","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/ijms25115874","volume":"25","author":"I Juresko","year":"2024","unstructured":"Juresko I, Pleic N, Gunjaca I, Torlak V, Brdar D, Punda A et al (2024) The Effect of Mediterranean Diet on Thyroid Gland Activity. Int J Mol Sci 25(11):34","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2862_CR170","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/nu13020529","volume":"13","author":"KL Pang","year":"2021","unstructured":"Pang KL, Lumintang JN, Chin KY (2021) Thyroid-Modulating Activities of Olive and Its Polyphenols: A Systematic Review. Nutrients 13(2):34","journal-title":"Nutrients"},{"issue":"2","key":"2862_CR171","first-page":"101","volume":"12","author":"F Rasekh","year":"2022","unstructured":"Rasekh F, Atashi-Nodoshan Z, Zarei A, Minaeifar AA, Changizi-Ashtiyani S, Afrasyabi Z (2022) Comparison of the effects of alcoholic extract of aerial parts of Anvillea garcinii and atorvastatin on the lipid profile and thyroid hormones in hypercholesterolemic rats. Avicenna J Phytomed 12(2):101\u2013108","journal-title":"Avicenna J Phytomed"},{"issue":"7","key":"2862_CR172","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0002-9343(00)00588-X","volume":"109","author":"MH Whittaker","year":"2000","unstructured":"Whittaker MH (2000) Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. Am J Med 109(7):600\u2013601","journal-title":"Am J Med"},{"issue":"1","key":"2862_CR173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3168\/jds.2012-5442","volume":"96","author":"SS Awaisheh","year":"2013","unstructured":"Awaisheh SS, Khalifeh MS, Al-Ruwaili MA, Khalil OM, Al-Ameri OH, Al-Groom R (2013) Effect of supplementation of probiotics and phytosterols alone or in combination on serum and hepatic lipid profiles and thyroid hormones of hypercholesterolemic rats. J Dairy Sci 96(1):9\u201315","journal-title":"J Dairy Sci"},{"issue":"4","key":"2862_CR174","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/nutrit\/nuv110","volume":"74","author":"P Felker","year":"2016","unstructured":"Felker P, Bunch R, Leung AM (2016) Concentrations of thiocyanate and goitrin in human plasma, their precursor concentrations in brassica vegetables, and associated potential risk for hypothyroidism. Nutr Rev 74(4):248\u2013258","journal-title":"Nutr Rev"},{"issue":"7","key":"2862_CR175","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms25073988","volume":"25","author":"A Galanty","year":"2024","unstructured":"Galanty A, Grudzinska M, Pazdziora W, Sluzaly P, Pasko P (2024) Do Brassica Vegetables Affect Thyroid Function?-A Comprehensive Systematic Review. Int J Mol Sci 25(7):23","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2862_CR176","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ptr.7410","volume":"36","author":"M Darand","year":"2022","unstructured":"Darand M, Alizadeh S, Mansourian M (2022) The effect of Brassica vegetables on blood glucose levels and lipid profiles in adults. A systematic review and meta-analysis. Phytother Res 36(5):1914\u20131929","journal-title":"Phytother Res"},{"issue":"8","key":"2862_CR177","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/nu13082531","volume":"13","author":"A Baranska","year":"2021","unstructured":"Baranska A, Blaszczuk A, Kanadys W, Baczewska B, Jedrych M, Wawryk-Gawda E et al (2021) Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women as a Potential Prevention Factor in Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 13(8):34","journal-title":"Nutrients"},{"issue":"3","key":"2862_CR178","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/thy.2006.16.249","volume":"16","author":"M Messina","year":"2006","unstructured":"Messina M, Redmond G (2006) Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16(3):249\u2013258","journal-title":"Thyroid"},{"issue":"12","key":"2862_CR179","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/clinem\/dgaa674","volume":"105","author":"CB Newman","year":"2020","unstructured":"Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG et al (2020) Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 105(12):34","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR180","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1874192401105010076","volume":"5","author":"CV Rizos","year":"2011","unstructured":"Rizos CV, Elisaf MS, Liberopoulos EN (2011) Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J 5:76\u201384","journal-title":"Open Cardiovasc Med J"},{"issue":"11","key":"2862_CR181","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1194\/jlr.M051664","volume":"55","author":"Y Bonde","year":"2014","unstructured":"Bonde Y, Breuer O, Lutjohann D, Sjoberg S, Angelin B, Rudling M (2014) Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res 55(11):2408\u20132415","journal-title":"J Lipid Res"},{"issue":"2","key":"2862_CR182","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","volume":"96","author":"LH Duntas","year":"2012","unstructured":"Duntas LH, Brenta G (2012) The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 96(2):269\u2013281","journal-title":"Med Clin North Am"},{"key":"2862_CR183","doi-asserted-by":"crossref","unstructured":"de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW. (1993) Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab. 76(1):121-6","DOI":"10.1210\/jcem.76.1.8421075"},{"issue":"8","key":"2862_CR184","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1172\/JCI107017","volume":"51","author":"EA Nikkila","year":"1972","unstructured":"Nikkila EA, Kekki M (1972) Plasma triglyceride metabolism in thyroid disease. J Clin Invest 51(8):2103\u20132114","journal-title":"J Clin Invest"},{"issue":"3","key":"2862_CR185","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1210\/jc.2011-2777","volume":"97","author":"E Fabbrini","year":"2012","unstructured":"Fabbrini E, Magkos F, Patterson BW, Mittendorfer B, Klein S (2012) Subclinical hypothyroidism and hyperthyroidism have opposite effects on hepatic very-low-density lipoprotein-triglyceride kinetics. J Clin Endocrinol Metab 97(3):E414\u2013E418","journal-title":"J Clin Endocrinol Metab"},{"issue":"10428","key":"2862_CR186","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(23)02016-0","volume":"403","author":"L Chaker","year":"2024","unstructured":"Chaker L, Cooper DS, Walsh JP, Peeters RP (2024) Hyperthyroidism. Lancet 403(10428):768\u2013780","journal-title":"Lancet"},{"key":"2862_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00228","volume":"7","author":"TY Wu","year":"2020","unstructured":"Wu TY, Wang CH, Tien N, Lin CL, Chu FY, Chang HY et al (2020) A population-based cohort study on the association of hyperthyroidism with the risk of hyperlipidemia and the effects of anti-thyroid drugs on hepatic gene expression. Front Med 7:228","journal-title":"Front Med"},{"key":"2862_CR188","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251372381","volume":"16","author":"T Nagamine","year":"2025","unstructured":"Nagamine T, Tanimura-Inagaki K, Nagao M, Kobayashi S, Shuto Y, Tamura H et al (2025) Impact of Graves hyperthyroidism treatment on lipid profiles and cholesterol dynamics: a prospective observational study. Ther Adv Endocrinol Metab 16:20420188251372381","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"24","key":"2862_CR189","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):3168\u20133209","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2862_CR190","doi-asserted-by":"publisher","first-page":"420","DOI":"10.31083\/ph.2014.3909R","volume":"69","author":"E Berta","year":"2014","unstructured":"Berta E, Harangi M, Zsiros N, Nagy EV, Paragh G, Bodor M (2014) Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. Pharmazie 69(6):420\u2013423","journal-title":"Pharmazie"},{"issue":"5","key":"2862_CR191","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10557-019-06904-x","volume":"33","author":"V Azemawah","year":"2019","unstructured":"Azemawah V, Movahed MR, Centuori P, Penaflor R, Riel PL, Situ S et al (2019) State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc Drugs Ther 33(5):625\u2013639","journal-title":"Cardiovasc Drugs Ther"},{"issue":"14","key":"2862_CR192","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"C Writing","year":"2022","unstructured":"Writing C, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM et al (2022) 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 80(14):1366\u20131418","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2862_CR193","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2169\/internalmedicine.4462-20","volume":"59","author":"A Hayashi","year":"2020","unstructured":"Hayashi A, Takano K, Kawakami Y, Hitomi M, Ohata Y, Suzuki A et al (2020) Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves\u2019 Disease. Intern Med 59(15):1827\u20131833","journal-title":"Intern Med"},{"issue":"6","key":"2862_CR194","doi-asserted-by":"publisher","first-page":"E1067","DOI":"10.1152\/ajpendo.00253.2004","volume":"288","author":"AL Riis","year":"2005","unstructured":"Riis AL, Jorgensen JO, Gjedde S, Norrelund H, Jurik AG, Nair KS et al (2005) Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. Am J Physiol Endocrinol Metab 288(6):E1067\u2013E1073","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"2862_CR195","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ajg.2016.28","volume":"111","author":"SA McClave","year":"2016","unstructured":"McClave SA, DiBaise JK, Mullin GE, Martindale RG (2016) ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient. Am J Gastroenterol 111(3):315\u2013334","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"2862_CR196","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1056\/NEJMra2214275","volume":"390","author":"SB Heymsfield","year":"2024","unstructured":"Heymsfield SB, Shapses SA (2024) Guidance on energy and macronutrients across the life span. N Engl J Med 390(14):1299\u20131310","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"2862_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP13155.GL","volume":"19","author":"JM Gonzalez-Campoy","year":"2013","unstructured":"Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L et al (2013) Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists\/the American College of Endocrinology and the Obesity Society. Endocr Pract 19(Suppl 3):1\u201382","journal-title":"Endocr Pract"},{"issue":"11","key":"2862_CR198","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029512","volume":"12","author":"T Wang","year":"2023","unstructured":"Wang T, Zhang X, Zhou N, Shen Y, Li B, Chen BE et al (2023) Association between Omega-3 fatty acid intake and dyslipidemia: A continuous dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc 12(11):e029512","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2862_CR199","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4158\/EP.15.3.254","volume":"15","author":"M Potenza","year":"2009","unstructured":"Potenza M, Via MA, Yanagisawa RT (2009) Excess thyroid hormone and carbohydrate metabolism. Endocr Pract 15(3):254\u2013262","journal-title":"Endocr Pract"},{"issue":"9","key":"2862_CR200","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","volume":"97","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH et al (2012) Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97(9):2969\u20132989","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/nu17020358","author":"S Scaglione","year":"2025","unstructured":"Scaglione S, Di Chiara T, Daidone M, Tuttolomondo A (2025) Effects of the Mediterranean diet on the components of metabolic syndrome concerning the cardiometabolic risk. Nutrients. https:\/\/doi.org\/10.3390\/nu17020358","journal-title":"Nutrients"},{"issue":"9","key":"2862_CR202","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1210\/jc.2019-01338","volume":"104","author":"JL Rosenzweig","year":"2019","unstructured":"Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR et al (2019) Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104(9):3939\u20133985","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR203","doi-asserted-by":"publisher","first-page":"1092837","DOI":"10.3389\/fendo.2022.1092837","volume":"13","author":"MT Macvanin","year":"2022","unstructured":"Macvanin MT, Gluvic Z, Zafirovic S, Gao X, Essack M, Isenovic ER (2022) The protective role of nutritional antioxidants against oxidative stress in thyroid disorders. Front Endocrinol (Lausanne) 13:1092837","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2862_CR204","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1210\/jc.2005-0960","volume":"91","author":"G Dimitriadis","year":"2006","unstructured":"Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Koukkou E et al (2006) Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrinol Metab 91(3):1112\u20131118","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2862_CR205","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/ijms22168503","volume":"22","author":"N Mir","year":"2021","unstructured":"Mir N, Chin SA, Riddell MC, Beaudry JL (2021) Genomic and Non-Genomic Actions of Glucocorticoids on Adipose Tissue Lipid Metabolism. Int J Mol Sci 22(16):34","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2862_CR206","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12864-025-11676-w","volume":"26","author":"M Piechota","year":"2025","unstructured":"Piechota M, Zieba M, Borczyk M, Golda S, Hajto J, Skupio U et al (2025) A cross-tissue transcriptomic approach decodes glucocorticoid receptor-dependent links to human metabolic phenotypes. BMC Genomics 26(1):462","journal-title":"BMC Genomics"},{"issue":"5","key":"2862_CR207","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1093\/ejendo\/lvad048","volume":"188","author":"F Quagliarini","year":"2023","unstructured":"Quagliarini F, Makris K, Friano ME, Uhlenhaut NH (2023) EJE Prize 2023: genes on steroids-genomic control of hepatic metabolism by the glucocorticoid receptor. Eur J Endocrinol 188(5):R111\u2013R130","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2862_CR208","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cmet.2021.06.004","volume":"33","author":"W Hu","year":"2021","unstructured":"Hu W, Jiang C, Kim M, Yang W, Zhu K, Guan D et al (2021) Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metab 33(8):1592\u20131609","journal-title":"Cell Metab"},{"issue":"1","key":"2862_CR209","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1152\/ajpendo.00544.2001","volume":"283","author":"CB Djurhuus","year":"2002","unstructured":"Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE et al (2002) Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab 283(1):E172\u2013E177","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2862_CR210","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/dom.12899","volume":"19","author":"RH Stimson","year":"2017","unstructured":"Stimson RH, Anderson AJ, Ramage LE, Macfarlane DP, de Beaux AC, Mole DJ et al (2017) Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct. Diabetes Obes Metab 19(6):883\u2013891","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2862_CR211","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jama.2025.5485","volume":"334","author":"A Vaidya","year":"2025","unstructured":"Vaidya A, Findling J, Bancos I (2025) Adrenal Insufficiency in Adults: A Review. JAMA 334(8):714\u2013725","journal-title":"JAMA"},{"issue":"12","key":"2862_CR212","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1210\/jc.2019-00420","volume":"104","author":"R Hayashi","year":"2019","unstructured":"Hayashi R, Tamada D, Murata M, Kitamura T, Mukai K, Maeda N et al (2019) Glucocorticoid replacement affects serum adiponectin levels and HDL-C in patients with secondary adrenal insufficiency. J Clin Endocrinol Metab 104(12):5814\u20135822","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116137","volume":"223","author":"A Bavaresco","year":"2024","unstructured":"Bavaresco A, Mazzeo P, Lazzara M, Barbot M (2024) Adipose tissue in cortisol excess: what Cushings syndrome can teach us? Biochem Pharmacol 223:116137","journal-title":"Biochem Pharmacol"},{"key":"2862_CR214","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-2895-8_6","volume":"872","author":"RM de Guia","year":"2015","unstructured":"de Guia RM, Herzig S (2015) How do glucocorticoids regulate lipid metabolism? Adv Exp Med Biol 872:127\u2013144","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"2862_CR215","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","volume":"60","author":"AJ Peckett","year":"2011","unstructured":"Peckett AJ, Wright DC, Riddell MC (2011) The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60(11):1500\u20131510","journal-title":"Metabolism"},{"key":"2862_CR216","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1489254","volume":"16","author":"L Tomasello","year":"2025","unstructured":"Tomasello L, Coppola A, Pizzolanti G, Giordano C, Arnaldi G, Guarnotta V (2025) Dual-release hydrocortisone treatment improves serum and peripheral blood mononuclear cell inflammatory and immune profiles in patients with autoimmune primary adrenal insufficiency. Front Immunol 16:1489254","journal-title":"Front Immunol"},{"issue":"6","key":"2862_CR217","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1096\/fj.07-094144","volume":"22","author":"M Christ-Crain","year":"2008","unstructured":"Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G et al (2008) AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing\u2019s syndrome. FASEB J 22(6):1672\u20131683","journal-title":"FASEB J"},{"issue":"12","key":"2862_CR218","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1210\/clinem\/dgad370","volume":"108","author":"RA Dineen","year":"2023","unstructured":"Dineen RA, Martin-Grace J, Ahmed KMS, Taylor AE, Shaheen F, Schiffer L et al (2023) Tissue Glucocorticoid metabolism in adrenal insufficiency: a prospective study of dual-release Hydrocortisone therapy. J Clin Endocrinol Metab 108(12):3178\u20133189","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2862_CR219","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2265.2005.02320.x","volume":"63","author":"A Crown","year":"2005","unstructured":"Crown A, Lightman S (2005) Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 63(5):483\u2013492","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2862_CR220","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/BF03345773","volume":"32","author":"R Giordano","year":"2009","unstructured":"Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo E, Berardelli R et al (2009) Metabolic and cardiovascular profile in patients with Addison\u2019s disease under conventional glucocorticoid replacement. J Endocrinol Invest 32(11):917\u2013923","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2862_CR221","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","volume":"97","author":"G Johannsson","year":"2012","unstructured":"Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B et al (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97(2):473\u2013481","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2862_CR222","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Oksnes M (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172(5):619\u2013626","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2862_CR223","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","volume":"51","author":"R Giordano","year":"2016","unstructured":"Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R et al (2016) Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison\u2019s disease. Endocrine 51(2):360\u2013368","journal-title":"Endocrine"},{"issue":"5","key":"2862_CR224","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cen.13554","volume":"88","author":"V Guarnotta","year":"2018","unstructured":"Guarnotta V, Ciresi A, Pillitteri G, Giordano C (2018) Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin Endocrinol (Oxf) 88(5):665\u2013672","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2862_CR225","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V et al (2018) Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6(3):173\u2013185","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2862_CR226","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40618-022-01940-1","volume":"46","author":"V Gasco","year":"2023","unstructured":"Gasco V, Giannelli J, Campioni L, Arvat E, Ghigo E, Grottoli S et al (2023) Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency. J Endocrinol Invest 46(3):587\u2013597","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2862_CR227","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EC-17-0368","volume":"7","author":"LM Mongioi","year":"2018","unstructured":"Mongioi LM, Condorelli RA, La Vignera S, Calogero AE (2018) Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr Connect 7(1):211\u2013219","journal-title":"Endocr Connect"},{"key":"2862_CR228","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.steroids.2014.07.015","volume":"92","author":"JW Koper","year":"2014","unstructured":"Koper JW, van Rossum EF, van den Akker EL (2014) Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 92:62\u201373","journal-title":"Steroids"},{"issue":"6","key":"2862_CR229","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/j.1365-2265.2012.04439.x","volume":"77","author":"R Giordano","year":"2012","unstructured":"Giordano R, Marzotti S, Berardelli R, Karamouzis I, Brozzetti A, D\u2019Angelo V et al (2012) BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison\u2019s disease. Clin Endocrinol (Oxf) 77(6):863\u2013870","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2862_CR230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EC-16-0081","volume":"6","author":"M Quinkler","year":"2017","unstructured":"Quinkler M, Ekman B, Marelli C, Uddin S, Zelissen P, Murray RD et al (2017) Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect 6(1):1\u20138","journal-title":"Endocr Connect"},{"issue":"3","key":"2862_CR231","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1210\/clinem\/dgae822","volume":"110","author":"SD Steintorsdottir","year":"2025","unstructured":"Steintorsdottir SD, Oksnes M, Jorgensen AP, Husebye ES (2025) Extended-release hydrocortisone formulations-is there a clinically meaningful benefit? J Clin Endocrinol Metab 110(3):e566\u2013e573","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2862_CR232","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1210\/jc.2013-4253","volume":"99","author":"M Oksnes","year":"2014","unstructured":"Oksnes M, Bjornsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM et al (2014) Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison\u2019s disease: a randomized clinical trial. J Clin Endocrinol Metab 99(5):1665\u20131674","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR233","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD et al (2016) Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101(2):364\u2013389","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2862_CR234","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2006-0524","volume":"91","author":"H Filipsson","year":"2006","unstructured":"Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91(10):3954\u20133961","journal-title":"J Clin Endocrinol Metab"},{"issue":"409","key":"2862_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120479","volume":"2025","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokgozoglu L, Badimon L, Baigent C et al (2025) Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2025(409):120479","journal-title":"Atherosclerosis"},{"issue":"12","key":"2862_CR236","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jacc.2023.01.024","volume":"81","author":"MJ Domanski","year":"2023","unstructured":"Domanski MJ, Wu CO, Tian X, Hasan AA, Ma X, Huang Y et al (2023) Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors. J Am Coll Cardiol 81(12):1151\u20131161","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2862_CR237","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2012.14312","volume":"308","author":"JT Wilkins","year":"2012","unstructured":"Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM (2012) Lifetime risk and years lived free of total cardiovascular disease. JAMA 308(17):1795\u20131801","journal-title":"JAMA"},{"issue":"6","key":"2862_CR238","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1210\/jc.2018-02298","volume":"104","author":"J Skov","year":"2019","unstructured":"Skov J, Sundstrom A, Ludvigsson JF, Kampe O, Bensing S (2019) Sex-specific risk of cardiovascular disease in autoimmune Addison disease-A population-based cohort study. J Clin Endocrinol Metab 104(6):2031\u20132040","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR239","doi-asserted-by":"crossref","unstructured":"Krysiak R, Claahsen-van der Grinten HL, Reisch N, Touraine P, Falhammar H (2025) Cardiometabolic Aspects of Congenital Adrenal Hyperplasia. Endocr Rev. 46(1):80-148","DOI":"10.1210\/endrev\/bnae026"},{"issue":"3","key":"2862_CR240","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MED.0b013e3283398ee2","volume":"17","author":"CA Allan","year":"2010","unstructured":"Allan CA, McLachlan RI (2010) Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17(3):224\u2013232","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2862_CR241","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1365-2265.2004.02007.x","volume":"60","author":"F Lanfranco","year":"2004","unstructured":"Lanfranco F, Zitzmann M, Simoni M, Nieschlag E (2004) Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 60(4):500\u2013507","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2862_CR242","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1210\/jc.2012-2102","volume":"97","author":"GP Finkielstain","year":"2012","unstructured":"Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC et al (2012) Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 97(12):4429\u20134438","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2862_CR243","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-21-0794","volume":"186","author":"A Prete","year":"2021","unstructured":"Prete A, Auchus RJ, Ross RJ (2021) Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol 186(1):R1\u2013R14","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2862_CR244","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1210\/jc.2018-01862","volume":"103","author":"S Tamhane","year":"2018","unstructured":"Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, Prokop LJ, Bancos I, Speiser PW et al (2018) Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 103(11):4097\u20134103","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2862_CR245","doi-asserted-by":"publisher","first-page":"e1106","DOI":"10.1210\/clinem\/dgab767","volume":"107","author":"A Delai","year":"2022","unstructured":"Delai A, Gomes PM, Foss-Freitas MC, Elias J, Antonini SR, Castro M et al (2022) Hyperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 107(3):e1106\u2013e1116","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2862_CR246","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12902-023-01499-9","volume":"23","author":"TM Espinosa Reyes","year":"2023","unstructured":"Espinosa Reyes TM, Pesantez Velepucha AK, Cabrera Rego JO, Valdes Gomez W, Dominguez Alonso E, Falhammar H (2023) Cardiovascular risk in Cuban adolescents and young adults with congenital adrenal hyperplasia. BMC Endocr Disord 23(1):241","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"2862_CR247","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1053\/meta.2000.6261","volume":"49","author":"D Botero","year":"2000","unstructured":"Botero D, Arango A, Danon M, Lifshitz F (2000) Lipid profile in congenital adrenal hyperplasia. Metabolism 49(6):790\u2013793","journal-title":"Metabolism"},{"issue":"2","key":"2862_CR248","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000503287","volume":"92","author":"HS Farghaly","year":"2019","unstructured":"Farghaly HS, Metwalley KA, Raafat DM, Algowhary M, Said GM (2019) Epicardial fat thickness in children with subclinical hypothyroidism and its relationship to subclinical atherosclerosis: a pilot study. Horm Res Paediatr 92(2):99\u2013105","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"2862_CR249","doi-asserted-by":"publisher","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","volume":"106","author":"DP Merke","year":"2021","unstructured":"Merke DP, Mallappa A, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A et al (2021) Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 106(5):e2063\u2013e2077","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2862_CR250","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/ejendo\/lvaf130","volume":"193","author":"W Arlt","year":"2025","unstructured":"Arlt W, Brac de la Perriere A, Hirschberg AL, Merke DP, Newell-Price JDC, Prete A et al (2025) Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules. Eur J Endocrinol 193(1):76\u201384","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2862_CR251","first-page":"34","volume":"15","author":"TTH Nguyen","year":"2025","unstructured":"Nguyen TTH, Le KM, Tran TAT, Nguyen KN, Can TBN, Bui PT et al (2025) Growth Assessment and Nutritional Status in Children with Congenital Adrenal Hyperplasia-A Cross-Sectional Study from a Vietnamese Tertiary Pediatric Center. Diagnostics (Basel). 15(12):34","journal-title":"Diagnostics (Basel)."},{"key":"2862_CR252","first-page":"1","volume":"3","author":"LN Overholtzer","year":"2025","unstructured":"Overholtzer LN, Luo S, Lim SL, Pickering TA, Fraga NR, Kim E et al (2025) Impaired Dietary Decision-Making in Children and Adolescents with Congenital Adrenal Hyperplasia. Horm Res Paediatr 3:1\u201310","journal-title":"Horm Res Paediatr"},{"key":"2862_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.hctj.2024.100057","volume":"2","author":"J Dennis","year":"2024","unstructured":"Dennis J, Pitts L, Matalka L, Mays LC (2024) Comprehensive adolescent healthcare transition program for congenital adrenal hyperplasia: a quality improvement initiative. Health Care Transitions 2:100057","journal-title":"Health Care Transitions"},{"issue":"2","key":"2862_CR254","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ecl.2005.01.010","volume":"34","author":"R Pivonello","year":"2005","unstructured":"Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome. Endocrinol Metab Clin North Am 34(2):327\u2013339","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2862_CR255","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A (2016) Complications of Cushings syndrome: state of the art. Lancet Diabetes Endocrinol 4(7):611\u2013629","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2862_CR256","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/me.2008-0464","volume":"23","author":"C Xu","year":"2009","unstructured":"Xu C, He J, Jiang H, Zu L, Zhai W, Pu S et al (2009) Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol 23(8):1161\u20131170","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2862_CR257","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/JOE-08-0054","volume":"197","author":"DP Macfarlane","year":"2008","unstructured":"Macfarlane DP, Forbes S, Walker BR (2008) Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197(2):189\u2013204","journal-title":"J Endocrinol"},{"issue":"11","key":"2862_CR258","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1194\/jlr.M900176-JLR200","volume":"50","author":"WJ Shen","year":"2009","unstructured":"Shen WJ, Patel S, Miyoshi H, Greenberg AS, Kraemer FB (2009) Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. J Lipid Res 50(11):2306\u20132313","journal-title":"J Lipid Res"},{"issue":"5","key":"2862_CR259","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1172\/JCI116821","volume":"92","author":"SK Fried","year":"1993","unstructured":"Fried SK, Russell CD, Grauso NL, Brolin RE (1993) Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 92(5):2191\u20132198","journal-title":"J Clin Invest"},{"issue":"3","key":"2862_CR260","first-page":"820","volume":"79","author":"M Ottosson","year":"1994","unstructured":"Ottosson M, Vikman-Adolfsson K, Enerback S, Olivecrona G, Bjorntorp P (1994) The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 79(3):820\u2013825","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2862_CR261","doi-asserted-by":"publisher","first-page":"C198","DOI":"10.1152\/ajpcell.00045.2010","volume":"300","author":"JE Campbell","year":"2011","unstructured":"Campbell JE, Peckett AJ, D\u2019Souza AM, Hawke TJ, Riddell MC (2011) Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol 300(1):C198-209","journal-title":"Am J Physiol Cell Physiol"},{"issue":"10","key":"2862_CR262","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2008.08.005","volume":"19","author":"H Tilg","year":"2008","unstructured":"Tilg H, Moschen AR (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19(10):371\u2013379","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2862_CR263","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbadis.2013.05.029","volume":"1842","author":"MJ Lee","year":"2014","unstructured":"Lee MJ, Pramyothin P, Karastergiou K, Fried SK (2014) Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta 1842(3):473\u2013481","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2862_CR264","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ijo.2016.57","volume":"40","author":"C Yan","year":"2016","unstructured":"Yan C, Yang H, Wang Y, Dong Y, Yu F, Wu Y et al (2016) Increased glycogen synthase kinase-3beta and hexose-6-phosphate dehydrogenase expression in adipose tissue may contribute to glucocorticoid-induced mouse visceral adiposity. Int J Obes (Lond) 40(8):1233\u20131241","journal-title":"Int J Obes (Lond)"},{"issue":"1-2","key":"2862_CR265","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mce.2014.06.001","volume":"393","author":"B Feng","year":"2014","unstructured":"Feng B, He Q, Xu H (2014) FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice. Mol Cell Endocrinol 393(1\u20132):46\u201355","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 1","key":"2862_CR266","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","volume":"92","author":"G Arnaldi","year":"2010","unstructured":"Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M (2010) Pathophysiology of dyslipidemia in Cushings syndrome. Neuroendocrinology 92(Suppl 1):86\u201390","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2862_CR267","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","volume":"1","author":"BB Kahn","year":"2005","unstructured":"Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1(1):15\u201325","journal-title":"Cell Metab"},{"issue":"12","key":"2862_CR268","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1210\/jc.2008-1297","volume":"93","author":"B Kola","year":"2008","unstructured":"Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M et al (2008) Changes in adenosine 5\u2019-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing\u2019s syndrome. J Clin Endocrinol Metab 93(12):4969\u20134973","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR269","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","volume":"61","author":"T Mancini","year":"2004","unstructured":"Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing\u2019s syndrome according to 1999 WHO\/ISH guidelines. Clin Endocrinol (Oxf) 61(6):768\u2013777","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2862_CR270","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1210\/jc.2001-011766","volume":"87","author":"L Tauchmanova","year":"2002","unstructured":"Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA et al (2002) Patients with subclinical Cushing\u2019s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87(11):4872\u20134878","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR271","unstructured":"Feingold KR (2000) Dyslipidemia in Patients with Diabetes. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth (MA)."},{"issue":"1","key":"2862_CR272","first-page":"36","volume":"8","author":"Z Li","year":"2022","unstructured":"Li Z, Zhang C, Geng C, Song Y (2022) Metabolic profile differences in ACTH-dependent and ACTH-independent Cushing syndrome. Chronic Dis Transl Med 8(1):36\u201340","journal-title":"Chronic Dis Transl Med"},{"issue":"6","key":"2862_CR273","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88(6):2527\u20132533","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2862_CR274","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000314294","volume":"92","author":"Y Greenman","year":"2010","unstructured":"Greenman Y (2010) Management of dyslipidemia in Cushings syndrome. Neuroendocrinology 92(Suppl 1):91\u201395","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2862_CR275","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1055\/a-0879-5122","volume":"51","author":"A Dhingra","year":"2019","unstructured":"Dhingra A, Ganie MA, Dharmshaktu P, Chakraborty S, Jyotsna VP, Gupta N (2019) Pattern of lipid abnormalities among South Asian Indians with Cushings syndrome and the short term impact of surgical correction of hypercortisolism. Horm Metab Res 51(5):309\u2013314","journal-title":"Horm Metab Res"},{"issue":"3","key":"2862_CR276","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","volume":"75","author":"R Giordano","year":"2011","unstructured":"Giordano R, Picu A, Marinazzo E, D\u2019Angelo V, Berardelli R, Karamouzis I et al (2011) Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75(3):354\u2013360","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2862_CR277","first-page":"2664","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M et al (1999) Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664\u20132672","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR278","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1507\/endocrj.43.645","volume":"43","author":"TC Friedman","year":"1996","unstructured":"Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R et al (1996) Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 43(6):645\u2013655","journal-title":"Endocr J"},{"issue":"4","key":"2862_CR279","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/HYPERTENSIONAHA.109.138248","volume":"54","author":"JS Orr","year":"2009","unstructured":"Orr JS, Dengo AL, Rivero JM, Davy KP (2009) Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 54(4):763\u2013768","journal-title":"Hypertension"},{"issue":"4","key":"2862_CR280","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/EJE-14-0556","volume":"172","author":"FM van Haalen","year":"2015","unstructured":"van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushings disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143\u2013R149","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2862_CR281","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11102-015-0645-6","volume":"18","author":"ST Sharma","year":"2015","unstructured":"Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushings disease. Pituitary 18(2):188\u2013194","journal-title":"Pituitary"},{"issue":"25","key":"2862_CR282","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"group Sw","year":"2021","unstructured":"group Sw, collaboration ESCCr (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42(25):2439\u20132454","journal-title":"Eur Heart J"},{"issue":"5","key":"2862_CR283","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al (2008) The diagnosis of Cushings syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(5):1526\u20131540","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2862_CR284","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12020-016-0984-8","volume":"56","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, De Martino MC, De Leo M, Simeoli C, Colao A (2017) Cushings disease: the burden of illness. Endocrine 56(1):10\u201318","journal-title":"Endocrine"},{"issue":"3","key":"2862_CR285","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2265.2003.01987.x","volume":"60","author":"M Krsek","year":"2004","unstructured":"Krsek M, Silha JV, Jezkova J, Hana V, Marek J, Weiss V et al (2004) Adipokine levels in Cushing\u2019s syndrome; elevated resistin levels in female patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 60(3):350\u2013357","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2862_CR286","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1530\/EJE-15-0566","volume":"173","author":"I Perogamvros","year":"2015","unstructured":"Perogamvros I, Vassiliadi DA, Karapanou O, Botoula E, Tzanela M, Tsagarakis S (2015) Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. Eur J Endocrinol 173(6):719\u2013725","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2862_CR287","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11255-011-9950-9","volume":"43","author":"M Miyazato","year":"2011","unstructured":"Miyazato M, Ishidoya S, Satoh F, Morimoto R, Kaiho Y, Yamada S et al (2011) Surgical outcomes of laparoscopic adrenalectomy for patients with Cushing\u2019s and subclinical Cushing\u2019s syndrome: a single center experience. Int Urol Nephrol 43(4):975\u2013981","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"2862_CR288","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A (2022) The dopaminergic control of Cushings syndrome. J Endocrinol Invest 45(7):1297\u20131315","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2862_CR289","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P et al (2013) Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98(4):299\u2013310","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2862_CR290","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","volume":"61","author":"A Albani","year":"2018","unstructured":"Albani A, Ferrau F, Ciresi A, Pivonello R, Scaroni C, Iacuaniello D et al (2018) Pasireotide treatment reduces cardiometabolic risk in Cushing\u2019s disease patients: an Italian, multicenter study. Endocrine 61(1):118\u2013124","journal-title":"Endocrine"},{"issue":"10","key":"2862_CR291","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2012) A 12-month phase 3 study of pasireotide in Cushings disease. N Engl J Med 366(10):914\u2013924","journal-title":"N Engl J Med"},{"issue":"1","key":"2862_CR292","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0022-2275(20)38566-7","volume":"29","author":"TA Miettinen","year":"1988","unstructured":"Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29(1):43\u201351","journal-title":"J Lipid Res"},{"issue":"1","key":"2862_CR293","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0300-2977(97)00010-7","volume":"51","author":"AF Stalenhoef","year":"1997","unstructured":"Stalenhoef AF, Stuyt PM, de Graaf J (1997) Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin. Neth J Med 51(1):10\u201315","journal-title":"Neth J Med"},{"issue":"6","key":"2862_CR294","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1530\/EJE-22-0506","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Auchus RJ, Greenman Y, Zacharieva S, Geer EB, Salvatori R et al (2022) Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur J Endocrinol 187(6):859\u2013871","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2862_CR295","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","volume":"100","author":"E Daniel","year":"2015","unstructured":"Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K et al (2015) Effectiveness of Metyrapone in treating Cushings syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 100(11):4146\u20134154","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2862_CR296","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8(9):748\u2013761","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2862_CR297","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-15-0946","volume":"174","author":"M Kroiss","year":"2016","unstructured":"Kroiss M, Plonne D, Kendl S, Schirmer D, Ronchi CL, Schirbel A et al (2016) Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 174(3):343\u2013353","journal-title":"Eur J Endocrinol"},{"key":"2862_CR298","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/624962","volume":"2013","author":"H Shawa","year":"2013","unstructured":"Shawa H, Deniz F, Bazerbashi H, Hernandez M, Vassilopoulou-Sellin R, Jimenez C et al (2013) Mitotane-induced hyperlipidemia: a retrospective cohort study. Int J Endocrinol 2013:624962","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2862_CR299","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049","journal-title":"J Clin Endocrinol Metab"},{"key":"2862_CR300","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C et al (2020) Medical Treatment of Cushing\u2019s Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol (Lausanne) 11:648","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2862_CR301","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/BF03347462","volume":"34","author":"MA Minetto","year":"2011","unstructured":"Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D\u2019Antona G (2011) Steroid myopathy: some unresolved issues. J Endocrinol Invest 34(5):370\u2013375","journal-title":"J Endocrinol Invest"},{"key":"2862_CR302","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","volume":"201","author":"G Savarese","year":"2015","unstructured":"Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P (2015) Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol 201:247\u2013252","journal-title":"Int J Cardiol"},{"issue":"3","key":"2862_CR303","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jacl.2018.03.078","volume":"12","author":"ED Tsakiridou","year":"2018","unstructured":"Tsakiridou ED, Liberopoulos E, Giotaki Z, Tigas S (2018) Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. J Clin Lipidol 12(3):826\u2013829","journal-title":"J Clin Lipidol"},{"key":"2862_CR304","doi-asserted-by":"publisher","DOI":"10.3390\/nu15214647","author":"V Guarnotta","year":"2023","unstructured":"Guarnotta V, Amodei R, Di Gaudio F, Giordano C (2023) Nutritional intervention in Cushings disease: the ketogenic diets effects on metabolic comorbidities and adrenal steroids. Nutrients. https:\/\/doi.org\/10.3390\/nu15214647","journal-title":"Nutrients"},{"key":"2862_CR305","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12111033","author":"MK Dugandzic","year":"2022","unstructured":"Dugandzic MK, Pierre-Michel EC, Kalayjian T (2022) Ketogenic diet initially masks symptoms of hypercortisolism in Cushings disease. Metabolites. https:\/\/doi.org\/10.3390\/metabo12111033","journal-title":"Metabolites"},{"key":"2862_CR306","doi-asserted-by":"publisher","DOI":"10.3390\/nu14050973","author":"V Guarnotta","year":"2022","unstructured":"Guarnotta V, Di Gaudio F, Giordano C (2022) Vitamin D deficiency in Cushings disease: before and after its supplementation. Nutrients. https:\/\/doi.org\/10.3390\/nu14050973","journal-title":"Nutrients"},{"issue":"Pt 2","key":"2862_CR307","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.mce.2015.06.031","volume":"418","author":"G Corona","year":"2015","unstructured":"Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M (2015) Obesity and late-onset hypogonadism. Mol Cell Endocrinol 418(Pt 2):120\u2013133","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2862_CR308","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/obr.12282","volume":"16","author":"DM Kelly","year":"2015","unstructured":"Kelly DM, Jones TH (2015) Testosterone and obesity. Obes Rev 16(7):581\u2013606","journal-title":"Obes Rev"},{"issue":"1","key":"2862_CR309","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cen.13723","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann M (2018) Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol (Oxf) 89(1):11\u201321","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1-2","key":"2862_CR310","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jsbmb.2008.12.022","volume":"114","author":"F Saad","year":"2009","unstructured":"Saad F, Gooren L (2009) The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol 114(1\u20132):40\u201343","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"2862_CR311","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1743-6109.2010.01991.x","volume":"8","author":"G Corona","year":"2011","unstructured":"Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F et al (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8(1):272\u2013283","journal-title":"J Sex Med"},{"issue":"2","key":"2862_CR312","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.atherosclerosis.2009.04.016","volume":"207","author":"TH Jones","year":"2009","unstructured":"Jones TH, Saad F (2009) The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207(2):318\u2013327","journal-title":"Atherosclerosis"},{"issue":"5","key":"2862_CR313","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-11-0447","volume":"165","author":"G Corona","year":"2011","unstructured":"Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165(5):687\u2013701","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2862_CR314","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JOE-12-0455","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH (2013) Testosterone: A metabolic hormone in health and disease. J Endocrinol 217(3):R25-45","journal-title":"J Endocrinol"},{"key":"2862_CR315","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19148677","author":"J Sanz-Canovas","year":"2022","unstructured":"Sanz-Canovas J, Lopez-Sampalo A, Cobos-Palacios L, Ricci M, Hernandez-Negrin H, Mancebo-Sevilla JJ et al (2022) Management of Type 2 Diabetes Mellitus in elderly patients with frailty and\/or sarcopenia. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph19148677","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2862_CR316","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00391-023-02235-7","volume":"57","author":"S Schluessel","year":"2024","unstructured":"Schluessel S, Bidlingmaier M, Martini S, Reincke M, Reisch N, Schaupp A et al (2024) Hypogonadism is frequent in very old men with multimorbidity and is associated with anemia and sarcopenia. Z Gerontol Geriatr 57(1):43\u201349","journal-title":"Z Gerontol Geriatr"},{"issue":"2","key":"2862_CR317","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1210\/er.2001-0025","volume":"24","author":"FC Wu","year":"2003","unstructured":"Wu FC, von Eckardstein A (2003) Androgens and coronary artery disease. Endocr Rev 24(2):183\u2013217","journal-title":"Endocr Rev"},{"issue":"9","key":"2862_CR318","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","volume":"43","author":"KK Berneis","year":"2002","unstructured":"Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43(9):1363\u20131379","journal-title":"J Lipid Res"},{"issue":"9","key":"2862_CR319","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40618-016-0480-2","volume":"39","author":"G Corona","year":"2016","unstructured":"Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M et al (2016) Testosterone supplementation and body composition: Results from a meta-analysis of observational studies. J Endocrinol Invest 39(9):967\u2013981","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2862_CR320","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/andr.13367","volume":"11","author":"G Corona","year":"2023","unstructured":"Corona G, Vena W, Pizzocaro A, Vignozzi L, Sforza A, Maggi M (2023) Testosterone therapy in diabetes and pre-diabetes. Andrology 11(2):204\u2013214","journal-title":"Andrology"},{"issue":"5","key":"2862_CR321","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM et al (2018) Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103(5):1715\u20131744","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2862_CR322","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17446651.2023.2296022","volume":"19","author":"G Corona","year":"2024","unstructured":"Corona G, Rastrelli G, Sparano C, Vignozzi L, Sforza A, Maggi M (2024) Advances in the treatment of functional male hypogonadism. Expert Rev Endocrinol Metab 19(2):163\u2013177","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"2862_CR323","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","volume":"2","author":"I Caruso","year":"2024","unstructured":"Caruso I, Cignarelli A, Sorice GP, Perrini S, Giorgino F (2024) Incretin-based therapies for the treatment of obesity-related diseases. NPJ Metab Health Dis 2(1):31","journal-title":"NPJ Metab Health Dis"},{"key":"2862_CR324","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, Di Gioia L, Di Molfetta S, Cignarelli A, Palmer SC, Natale P et al (2023) Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine 64:102181","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2862_CR325","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/dom.16042","volume":"27","author":"N Gregoric","year":"2025","unstructured":"Gregoric N, Sikonja J, Janez A, Jensterle M (2025) Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab 27(2):519\u2013528","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"2862_CR326","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS et al (2025) Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 392(21):2089\u20132099","journal-title":"N Engl J Med"},{"key":"2862_CR327","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158194","author":"VA Genchi","year":"2022","unstructured":"Genchi VA, Rossi E, Lauriola C, D\u2019Oria R, Palma G, Borrelli A et al (2022) Adipose tissue dysfunction and obesity-related male hypogonadism. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158194","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2862_CR328","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/andr.13357","volume":"11","author":"A Cignarelli","year":"2023","unstructured":"Cignarelli A, Santi D, Genchi VA, Conte E, Giordano F, Di Leo S et al (2023) Very low-calorie ketogenic diet rapidly augments testosterone levels in non-diabetic obese subjects. Andrology 11(2):234\u2013244","journal-title":"Andrology"},{"issue":"12","key":"2862_CR329","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","volume":"18","author":"AH Maas","year":"2010","unstructured":"Maas AH, Appelman YE (2010) Gender differences in coronary heart disease. Neth Heart J 18(12):598\u2013602","journal-title":"Neth Heart J"},{"key":"2862_CR330","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.maturitas.2022.08.001","volume":"166","author":"N Torosyan","year":"2022","unstructured":"Torosyan N, Visrodia P, Torbati T, Minissian MB, Shufelt CL (2022) Dyslipidemia in midlife women: approach and considerations during the menopausal transition. Maturitas 166:14\u201320","journal-title":"Maturitas"},{"issue":"6","key":"2862_CR331","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/01.HYP.0000223064.62762.0b","volume":"47","author":"MR Meyer","year":"2006","unstructured":"Meyer MR, Haas E, Barton M (2006) Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 47(6):1019\u20131026","journal-title":"Hypertension"},{"key":"2862_CR332","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.maturitas.2022.09.012","volume":"167","author":"P Anagnostis","year":"2023","unstructured":"Anagnostis P, Antza C, Trakatelli C, Lambrinoudaki I, Goulis DG, Kotsis V (2023) The effect of menopause on lipoprotein (a) concentrations: a systematic review and meta-analysis. Maturitas 167:39\u201345","journal-title":"Maturitas"},{"key":"2862_CR333","doi-asserted-by":"publisher","first-page":"1464803","DOI":"10.3389\/fendo.2024.1464803","volume":"15","author":"S Federici","year":"2024","unstructured":"Federici S, Rossetti R, Moleri S, Munari EV, Frixou M, Bonomi M et al (2024) Primary ovarian insufficiency: update on clinical and genetic findings. Front Endocrinol (Lausanne) 15:1464803","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"33","key":"2862_CR334","doi-asserted-by":"publisher","first-page":"9327","DOI":"10.1073\/pnas.1604558113","volume":"113","author":"ME Levine","year":"2016","unstructured":"Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L et al (2016) Menopause accelerates biological aging. Proc Natl Acad Sci U S A 113(33):9327\u20139332","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2862_CR335","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/GME.0000000000000710","volume":"24","author":"AH Shadyab","year":"2017","unstructured":"Shadyab AH, Macera CA, Shaffer RA, Jain S, Gallo LC, Gass ML et al (2017) Ages at menarche and menopause and reproductive lifespan as predictors of exceptional longevity in women: the Womens Health Initiative. Menopause 24(1):35\u201344","journal-title":"Menopause"},{"issue":"8","key":"2862_CR336","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/humrep\/deaa124","volume":"35","author":"D Zhu","year":"2020","unstructured":"Zhu D, Chung HF, Dobson AJ, Pandeya N, Brunner EJ, Kuh D et al (2020) Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 35(8):1933\u20131943","journal-title":"Hum Reprod"},{"issue":"5","key":"2862_CR337","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1210\/jc.2017-00131","volume":"102","author":"CM Gordon","year":"2017","unstructured":"Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M et al (2017) Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102(5):1413\u20131439","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2862_CR338","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1210\/jc.2003-030242","volume":"88","author":"MC Carr","year":"2003","unstructured":"Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88(6):2404\u20132411","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2862_CR339","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/GME.0000000000001143","volume":"25","author":"RC Thurston","year":"2018","unstructured":"Thurston RC, Karvonen-Gutierrez CA, Derby CA, El Khoudary SR, Kravitz HM, Manson JE (2018) Menopause versus chronologic aging: their roles in womens health. Menopause 25(8):849\u2013854","journal-title":"Menopause"},{"issue":"9","key":"2862_CR340","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1210\/jc.2016-2144","volume":"101","author":"SR El Khoudary","year":"2016","unstructured":"El Khoudary SR, Hutchins PM, Matthews KA, Brooks MM, Orchard TJ, Ronsein GE et al (2016) Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause. J Clin Endocrinol Metab 101(9):3419\u20133428","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2862_CR341","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.ajpath.2021.05.011","volume":"191","author":"M De Paoli","year":"2021","unstructured":"De Paoli M, Zakharia A, Werstuck GH (2021) The role of estrogen in insulin resistance: a review of clinical and preclinical data. Am J Pathol 191(9):1490\u20131498","journal-title":"Am J Pathol"},{"key":"2862_CR342","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031853","author":"K Yoh","year":"2023","unstructured":"Yoh K, Ikeda K, Horie K, Inoue S (2023) Roles of Estrogen, Estrogen Receptors, and Estrogen-Related Receptors in skeletal muscle: regulation of mitochondrial function. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24031853","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2862_CR343","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","volume":"19","author":"AJ Kattoor","year":"2017","unstructured":"Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL (2017) Oxidative stress in atherosclerosis. Curr Atheroscler Rep 19(11):42","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"2862_CR344","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jacl.2016.04.008","volume":"10","author":"SR El Khoudary","year":"2016","unstructured":"El Khoudary SR, Wang L, Brooks MM, Thurston RC, Derby CA, Matthews KA (2016) Increase HDL-C level over the menopausal transition is associated with greater atherosclerotic progression. J Clin Lipidol 10(4):962\u2013969","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2862_CR345","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12902-024-01663-9","volume":"24","author":"L Seidemann","year":"2024","unstructured":"Seidemann L, Lippold CP, Rohm CM, Eckel JC, Schicht G, Matz-Soja M et al (2024) Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes. BMC Endocr Disord 24(1):135","journal-title":"BMC Endocr Disord"},{"key":"2862_CR346","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2024.104253","volume":"164","author":"M Kunicki","year":"2024","unstructured":"Kunicki M, Rzewuska N, Gross-Kepinska K (2024) Immunophenotypic profiles and inflammatory markers in Premature Ovarian Insufficiency. J Reprod Immunol 164:104253","journal-title":"J Reprod Immunol"},{"issue":"25","key":"2862_CR347","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.jacc.2009.10.009","volume":"54","author":"KA Matthews","year":"2009","unstructured":"Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B et al (2009) Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54(25):2366\u20132373","journal-title":"J Am Coll Cardiol"},{"key":"2862_CR348","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.maturitas.2020.03.007","volume":"135","author":"P Anagnostis","year":"2020","unstructured":"Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F et al (2020) Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas 135:82\u201388","journal-title":"Maturitas"},{"issue":"5","key":"2862_CR349","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/gme.0b013e31816b4509","volume":"15","author":"EA Knauff","year":"2008","unstructured":"Knauff EA, Westerveld HE, Goverde AJ, Eijkemans MJ, Valkenburg O, van Santbrink EJ et al (2008) Lipid profile of women with premature ovarian failure. Menopause 15(5):919\u2013923","journal-title":"Menopause"},{"issue":"4","key":"2862_CR350","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/j.jacl.2024.04.125","volume":"18","author":"P Magdalena","year":"2024","unstructured":"Magdalena P, Olga KJ, Anna P, Robert J (2024) Unfavorably altered lipid profile in women with primary ovarian insufficiency. J Clin Lipidol 18(4):e602\u2013e609","journal-title":"J Clin Lipidol"},{"issue":"10","key":"2862_CR351","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3109\/09513590.2010.508852","volume":"27","author":"MP Rocha","year":"2011","unstructured":"Rocha MP, Marcondes JA, Barcellos CR, Hayashida SA, Curi DD, da Fonseca AM et al (2011) Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol 27(10):814\u2013819","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"2862_CR352","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(22)00076-6","volume":"10","author":"RE Nappi","year":"2022","unstructured":"Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T (2022) Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol 10(6):442\u2013456","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2862_CR353","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cen.15097","volume":"101","author":"CN Jayasena","year":"2024","unstructured":"Jayasena CN, Devine K, Barber K, Comninos AN, Conway GS, Crown A et al (2024) Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism. Clin Endocrinol (Oxf) 101(5):409\u2013442","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2862_CR354","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288(3):321\u2013333","journal-title":"JAMA"},{"issue":"9","key":"2862_CR355","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/GME.0000000000001326","volume":"26","author":"VM Miller","year":"2019","unstructured":"Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ et al (2019) The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause 26(9):1071\u20131084","journal-title":"Menopause"},{"key":"2862_CR356","first-page":"1","volume":"3","author":"T Li","year":"2025","unstructured":"Li T, Jiang NS, Kaskey J, Schnatz PF, Nudy M (2025) Hormone therapy and insulin resistance in non-diabetic postmenopausal women: a systematic review and meta-analysis. Climacteric 3:1\u20139","journal-title":"Climacteric"},{"issue":"5","key":"2862_CR357","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","volume":"8","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8(5):538\u2013554","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2862_CR358","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14211","volume":"54","author":"YL Zhang","year":"2024","unstructured":"Zhang YL, Xie L, Wu FL, Ding X, Hernandez-Wolters B, Gaman MA et al (2024) Comprehensive meta-analysis of the effects of oral medroxyprogesterone acetate plus conjugated equine oestrogens on the lipid profile in women: Insights from randomized controlled trials. Eur J Clin Invest 54(8):e14211","journal-title":"Eur J Clin Invest"},{"key":"2862_CR359","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105612","volume":"169","author":"C Lv","year":"2021","unstructured":"Lv C, Zhang W, Tan X, Shang X, Gaman MA, Salem H et al (2021) The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacol Res 169:105612","journal-title":"Pharmacol Res"},{"issue":"2","key":"2862_CR360","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.annonc.2024.10.824","volume":"36","author":"J Kim","year":"2025","unstructured":"Kim J, Munster PN (2025) Estrogens and breast cancer. Ann Oncol 36(2):134\u2013148","journal-title":"Ann Oncol"},{"issue":"10382","key":"2862_CR361","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P et al (2023) Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 401(10382):1091\u20131102","journal-title":"Lancet"},{"key":"2862_CR362","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079525","volume":"387","author":"K Schaudig","year":"2024","unstructured":"Schaudig K, Wang X, Bouchard C, Hirschberg AL, Cano A, Shapiro CMM et al (2024) Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ 387:e079525","journal-title":"BMJ"},{"issue":"2","key":"2862_CR363","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13697137.2020.1828854","volume":"24","author":"P Noll","year":"2021","unstructured":"Noll P, Campos CAS, Leone C, Zangirolami-Raimundo J, Noll M, Baracat EC et al (2021) Dietary intake and menopausal symptoms in postmenopausal women: a systematic review. Climacteric 24(2):128\u2013138","journal-title":"Climacteric"},{"issue":"9","key":"2862_CR364","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/gme.0b013e31824f606e","volume":"19","author":"CH Kroenke","year":"2012","unstructured":"Kroenke CH, Caan BJ, Stefanick ML, Anderson G, Brzyski R, Johnson KC et al (2012) Effects of a dietary intervention and weight change on vasomotor symptoms in the Women\u2019s Health Initiative. Menopause 19(9):980\u2013988","journal-title":"Menopause"},{"key":"2862_CR365","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.maturitas.2020.07.001","volume":"139","author":"A Cano","year":"2020","unstructured":"Cano A, Marshall S, Zolfaroli I, Bitzer J, Ceausu I, Chedraui P et al (2020) The Mediterranean diet and menopausal health: An EMAS position statement. Maturitas 139:90\u201397","journal-title":"Maturitas"},{"key":"2862_CR366","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.886824","volume":"13","author":"C Vetrani","year":"2022","unstructured":"Vetrani C, Barrea L, Rispoli R, Verde L, De Alteriis G, Docimo A et al (2022) Mediterranean Diet: What Are the Consequences for Menopause? Front Endocrinol (Lausanne) 13:886824","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2862_CR367","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1097\/GME.0000000000001812","volume":"28","author":"ND Barnard","year":"2021","unstructured":"Barnard ND, Kahleova H, Holtz DN, Del Aguila F, Neola M, Crosby LM et al (2021) The Womens Study for the Alleviation of Vasomotor Symptoms (WAVS): a randomized, controlled trial of a plant-based diet and whole soybeans for postmenopausal women. Menopause 28(10):1150\u20131156","journal-title":"Menopause"},{"issue":"1","key":"2862_CR368","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/GME.0000000000002080","volume":"30","author":"ND Barnard","year":"2023","unstructured":"Barnard ND, Kahleova H, Holtz DN, Znayenko-Miller T, Sutton M, Holubkov R et al (2023) A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. Menopause 30(1):80\u201387","journal-title":"Menopause"},{"issue":"12","key":"2862_CR369","volume":"2013","author":"A Lethaby","year":"2013","unstructured":"Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J (2013) Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013(12):CD001395","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2862_CR370","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14360","volume":"75","author":"J Li","year":"2021","unstructured":"Li J, Li H, Yan P, Guo L, Li J, Han J et al (2021) Efficacy and safety of phytoestrogens in the treatment of perimenopausal and postmenopausal depressive disorders: a systematic review and meta-analysis. Int J Clin Pract 75(10):e14360","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2862_CR371","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/GME.0000000000000363","volume":"22","author":"KM Newton","year":"2015","unstructured":"Newton KM, Reed SD, Uchiyama S, Qu C, Ueno T, Iwashita S et al (2015) A cross-sectional study of equol producer status and self-reported vasomotor symptoms. Menopause 22(5):489\u2013495","journal-title":"Menopause"},{"issue":"2","key":"2862_CR372","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3945\/jn.109.113886","volume":"140","author":"RL Simbalista","year":"2010","unstructured":"Simbalista RL, Sauerbronn AV, Aldrighi JM, Areas JA (2010) Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr 140(2):293\u2013297","journal-title":"J Nutr"},{"key":"2862_CR373","doi-asserted-by":"crossref","unstructured":"Kanadys W, Baranska A, Blaszczuk A, Polz-Dacewicz M, Drop B, Kanecki K, et al. (2021) Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 13(4).","DOI":"10.3390\/nu13041258"},{"issue":"4","key":"2862_CR374","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/13697137.2013.861814","volume":"17","author":"YR Liu","year":"2014","unstructured":"Liu YR, Jiang YL, Huang RQ, Yang JY, Xiao BK, Dong JX (2014) Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety. Climacteric 17(4):325\u2013335","journal-title":"Climacteric"},{"issue":"1","key":"2862_CR375","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3934\/publichealth.2024005","volume":"11","author":"C Goncalves","year":"2024","unstructured":"Goncalves C, Moreira H, Santos R (2024) Systematic review of Mediterranean diet interventions in menopausal women. AIMS Public Health 11(1):110\u2013129","journal-title":"AIMS Public Health"},{"issue":"10","key":"2862_CR376","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13733","volume":"2","author":"RV Seimon","year":"2019","unstructured":"Seimon RV, Wild-Taylor AL, Keating SE, McClintock S, Harper C, Gibson AA et al (2019) Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial. JAMA Netw Open 2(10):e1913733","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2862_CR377","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/nbu.12607","volume":"48","author":"S Yelland","year":"2023","unstructured":"Yelland S, Steenson S, Creedon A, Stanner S (2023) The role of diet in managing menopausal symptoms: a narrative review. Nutr Bull 48(1):43\u201365","journal-title":"Nutr Bull"},{"key":"2862_CR378","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.maturitas.2018.06.012","volume":"115","author":"M Glisic","year":"2018","unstructured":"Glisic M, Kastrati N, Musa J, Milic J, Asllanaj E, Portilla Fernandez E et al (2018) Phytoestrogen supplementation and body composition in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Maturitas 115:74\u201383","journal-title":"Maturitas"},{"key":"2862_CR379","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041326","author":"M Na Takuathung","year":"2023","unstructured":"Na Takuathung M, Klinjan P, Sakuludomkan W, Dukaew N, Inpan R, Kongta R et al (2023) Efficacy and safety of the Genistein nutraceutical product containing Vitamin E, Vitamin B3, and Ceramide on skin health in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12041326","journal-title":"J Clin Med"},{"issue":"7","key":"2862_CR380","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/GME.0000000000000380","volume":"22","author":"LO Carmignani","year":"2015","unstructured":"Carmignani LO, Pedro AO, Montemor EB, Arias VA, Costa-Paiva LH, Pinto-Neto AM (2015) Effects of a soy-based dietary supplement compared with low-dose hormone therapy on the urogenital system: a randomized, double-blind, controlled clinical trial. Menopause 22(7):741\u2013749","journal-title":"Menopause"},{"issue":"12","key":"2862_CR381","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.13507","volume":"44","author":"A Khanna","year":"2020","unstructured":"Khanna A, John F, Das S, Thomas J, Rao J, Maliakel B et al (2020) Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: a randomized, double-blinded, placebo-controlled study. J Food Biochem 44(12):e13507","journal-title":"J Food Biochem"},{"issue":"1","key":"2862_CR382","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GME.0000000000002098","volume":"30","author":"RB Grigolon","year":"2023","unstructured":"Grigolon RB, Ceolin G, Deng Y, Bambokian A, Koning E, Fabe J et al (2023) Effects of nutritional interventions on the severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta-analysis, and meta-regression. Menopause 30(1):95\u2013107","journal-title":"Menopause"},{"key":"2862_CR383","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113762","author":"L Barrea","year":"2021","unstructured":"Barrea L, Vetrani C, Altieri B, Verde L, Savastano S, Colao A et al (2021) The importance of being a Lark in post-menopausal women with obesity: a ploy to prevent Type 2 diabetes mellitus? Nutrients. https:\/\/doi.org\/10.3390\/nu13113762","journal-title":"Nutrients"},{"issue":"1","key":"2862_CR384","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1186\/s12967-025-06705-x","volume":"23","author":"L Verde","year":"2025","unstructured":"Verde L, Barrea L, Frias-Toral E, Zambrano-Villacres R, Simancas-Racines D, Memoli P et al (2025) Timing matters: lipid intake and its influence on menopausal-related symptoms. J Transl Med 23(1):934","journal-title":"J Transl Med"},{"issue":"4","key":"2862_CR385","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13679-022-00479-9","volume":"11","author":"L Verde","year":"2022","unstructured":"Verde L, Barrea L, Vetrani C, Frias-Toral E, Chapela SP, Jayawardena R et al (2022) Chronotype and Sleep Quality in Obesity: How Do They Change After Menopause? Curr Obes Rep 11(4):254\u2013262","journal-title":"Curr Obes Rep"},{"issue":"3","key":"2862_CR386","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/ejendo\/lvaf027","volume":"192","author":"A Gambineri","year":"2025","unstructured":"Gambineri A, Rosa S, Pandurevic S, Cecchetti C, Rotolo L, Dionese P et al (2025) Evolution of cardiovascular risk factors and the risk for cardiovascular events in a Caucasian population with polycystic ovary syndrome. Eur J Endocrinol 192(3):210\u2013219","journal-title":"Eur J Endocrinol"},{"key":"2862_CR387","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100666","volume":"18","author":"N Patel","year":"2024","unstructured":"Patel N, Mittal N, Wilkinson MJ, Taub PR (2024) Unique features of dyslipidemia in women across a lifetime and a tailored approach to management. Am J Prev Cardiol 18:100666","journal-title":"Am J Prev Cardiol"},{"issue":"7","key":"2862_CR388","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tem.2007.07.004","volume":"18","author":"E Diamanti-Kandarakis","year":"2007","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP (2007) Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18(7):280\u2013285","journal-title":"Trends Endocrinol Metab"},{"key":"2862_CR389","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020244","author":"TS Kolnikaj","year":"2024","unstructured":"Kolnikaj TS, Herman R, Janez A, Jensterle M (2024) The current and emerging role of statins in the treatment of PCOS: the evidence to date. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina60020244","journal-title":"Medicina (Kaunas)"},{"key":"2862_CR390","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000341683","volume":"40","author":"D Macut","year":"2013","unstructured":"Macut D, Bjekic-Macut J, Savic-Radojevic A (2013) Dyslipidemia and oxidative stress in PCOS. Front Horm Res 40:51\u201363","journal-title":"Front Horm Res"},{"issue":"3","key":"2862_CR391","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","volume":"95","author":"RA Wild","year":"2011","unstructured":"Wild RA, Rizzo M, Clifton S, Carmina E (2011) Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95(3):1073\u20139 e1-11","journal-title":"Fertil Steril"},{"issue":"1","key":"2862_CR392","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1742-1241.2008.01897.x","volume":"63","author":"K Berneis","year":"2009","unstructured":"Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I et al (2009) Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 63(1):56\u201362","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2862_CR393","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0895-4356(98)00010-9","volume":"51","author":"E Talbott","year":"1998","unstructured":"Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K et al (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51(5):415\u2013422","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2862_CR394","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1210\/jc.2007-1756","volume":"93","author":"O Valkenburg","year":"2008","unstructured":"Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH et al (2008) A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 93(2):470\u2013476","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2862_CR395","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/cen.14636","volume":"96","author":"MA Abdalla","year":"2022","unstructured":"Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Ostlundh L, Al-Rifai RH et al (2022) Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 96(4):443\u2013459","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2862_CR396","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/ejendo\/lvad082","volume":"189","author":"M Forslund","year":"2023","unstructured":"Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT et al (2023) Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol 189(1):S1\u2013S16","journal-title":"Eur J Endocrinol"},{"key":"2862_CR397","volume":"10","author":"AD Raval","year":"2011","unstructured":"Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 10:CD008565","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2862_CR398","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-2007-992933","volume":"26","author":"PH Kodaman","year":"2008","unstructured":"Kodaman PH, Duleba AJ (2008) Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med 26(1):127\u2013138","journal-title":"Semin Reprod Med"},{"issue":"7","key":"2862_CR399","volume":"7","author":"T Xiong","year":"2023","unstructured":"Xiong T, Fraison E, Kolibianaki E, Costello MF, Venetis C, Kostova EB (2023) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 7(7):CD008565","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2862_CR400","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","volume":"189","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT et al (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 189(2):G43\u2013G64","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2862_CR401","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40618-023-02169-2","volume":"47","author":"L Barrea","year":"2024","unstructured":"Barrea L, Verde L, Annunziata G, Camajani E, Caprio M, Sojat AS et al (2024) Role of Mediterranean diet in endocrine diseases: a joint overview by the endocrinologist and the nutritionist. J Endocrinol Invest 47(1):17\u201333","journal-title":"J Endocrinol Invest"},{"key":"2862_CR402","doi-asserted-by":"publisher","DOI":"10.3390\/nu11102278","author":"L Barrea","year":"2019","unstructured":"Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C et al (2019) Adherence to the Mediterranean Diet, dietary patterns and body composition in women with polycystic ovary syndrome (PCOS). Nutrients. https:\/\/doi.org\/10.3390\/nu11102278","journal-title":"Nutrients"},{"key":"2862_CR403","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113925","author":"L Barrea","year":"2021","unstructured":"Barrea L, Muscogiuri G, Pugliese G, de Alteriis G, Colao A, Savastano S (2021) Metabolically healthy obesity (MHO) vs. metabolically unhealthy obesity (MUO) phenotypes in PCOS: association with endocrine-metabolic profile, adherence to the Mediterranean Diet, and body composition. Nutrients. https:\/\/doi.org\/10.3390\/nu13113925","journal-title":"Nutrients"},{"key":"2862_CR404","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.876620","volume":"9","author":"S Mei","year":"2022","unstructured":"Mei S, Ding J, Wang K, Ni Z, Yu J (2022) Mediterranean diet combined with a low-carbohydrate dietary pattern in the treatment of overweight polycystic ovary syndrome patients. Front Nutr 9:876620","journal-title":"Front Nutr"},{"issue":"11","key":"2862_CR405","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08338","volume":"7","author":"N Saadati","year":"2021","unstructured":"Saadati N, Haidari F, Barati M, Nikbakht R, Mirmomeni G, Rahim F (2021) The effect of low glycemic index diet on the reproductive and clinical profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Heliyon 7(11):e08338","journal-title":"Heliyon"},{"key":"2862_CR406","doi-asserted-by":"publisher","first-page":"1578459","DOI":"10.3389\/fnut.2025.1578459","volume":"12","author":"L Zhang","year":"2025","unstructured":"Zhang L, Jin Y, Yang A, Yu X, Li Y, Wang X et al (2025) Optimizing carbohydrate quality: a path to better health for women with PCOS. Front Nutr 12:1578459","journal-title":"Front Nutr"},{"issue":"4","key":"2862_CR407","doi-asserted-by":"publisher","first-page":"555","DOI":"10.12891\/ceog3037.2016","volume":"43","author":"LH Sordia-Hernandez","year":"2016","unstructured":"Sordia-Hernandez LH, Ancer Rodriguez P, Saldivar Rodriguez D, Trejo Guzman S, Servin Zenteno ES, Guerrero Gonzalez G et al (2016) Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial. Clin Exp Obstet Gynecol 43(4):555\u2013559","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"3","key":"2862_CR408","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13679-023-00516-1","volume":"12","author":"E Camajani","year":"2023","unstructured":"Camajani E, Feraco A, Verde L, Moriconi E, Marchetti M, Colao A et al (2023) Ketogenic Diet as a Possible Non-pharmacological Therapy in Main Endocrine Diseases of the Female Reproductive System: A Practical Guide for Nutritionists. Curr Obes Rep 12(3):231\u2013249","journal-title":"Curr Obes Rep"},{"issue":"1","key":"2862_CR409","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12958-025-01411-1","volume":"23","author":"R Cannarella","year":"2025","unstructured":"Cannarella R, Rubulotta M, Leonardi A, Crafa A, Calvo A, Barbagallo F et al (2025) Effects of ketogenic diets on polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 23(1):74","journal-title":"Reprod Biol Endocrinol"},{"key":"2862_CR410","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1362226","volume":"11","author":"AS Kalsekar","year":"2024","unstructured":"Kalsekar AS, Abdelrahim DN, Faris ME (2024) Effect of calorie restriction and intermittent fasting on glucose homeostasis, lipid profile, inflammatory, and hormonal markers in patients with polycystic ovary syndrome: a systematic review. Front Nutr 11:1362226","journal-title":"Front Nutr"},{"key":"2862_CR411","doi-asserted-by":"publisher","DOI":"10.3390\/nu17152436","author":"Y Ranneh","year":"2025","unstructured":"Ranneh Y, Hamsho M, Shkorfu W, Terzi M, Fadel A (2025) Effect of intermittent fasting on anthropometric measurements, metabolic profile, and hormones in women with polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients. https:\/\/doi.org\/10.3390\/nu17152436","journal-title":"Nutrients"},{"key":"2862_CR412","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052256","author":"XA van Tienhoven","year":"2025","unstructured":"van Tienhoven XA, de Ruiz Chavez Gascon J, Cano-Herrera G, Sarkis Nehme JA, Souroujon Torun AA, Bautista Gonzalez MF et al (2025) Vitamin D in reproductive health disorders: a narrative review focusing on infertility, endometriosis, and polycystic ovarian syndrome. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26052256","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2862_CR413","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12902-025-01920-5","volume":"25","author":"M Yu","year":"2025","unstructured":"Yu M, Chen S, Liu X, Dong H, Wang DC (2025) The impact of vitamin D supplementation on glycemic control and lipid metabolism in polycystic ovary syndrome: a systematic review of randomized controlled trials. BMC Endocr Disord 25(1):110","journal-title":"BMC Endocr Disord"},{"issue":"36","key":"2862_CR414","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.2174\/1381612822666160720160634","volume":"22","author":"G Muscogiuri","year":"2016","unstructured":"Muscogiuri G, Palomba S, Lagana AS, Orio F (2016) Current insights into Inositol isoforms, Mediterranean and ketogenic diets for polycystic ovary syndrome: from bench to bedside. Curr Pharm Des 22(36):5554\u20135557","journal-title":"Curr Pharm Des"},{"key":"2862_CR415","doi-asserted-by":"publisher","DOI":"10.3390\/nu16223916","author":"D Martinez Guevara","year":"2024","unstructured":"Martinez Guevara D, Vidal Canas S, Palacios I, Gomez A, Estrada M, Gallego J et al (2024) Effectiveness of probiotics, prebiotics, and synbiotics in managing insulin resistance and hormonal imbalance in women with polycystic ovary syndrome (PCOS): a systematic review of randomized clinical trials. Nutrients. https:\/\/doi.org\/10.3390\/nu16223916","journal-title":"Nutrients"},{"issue":"1","key":"2862_CR416","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-022-01208-y","volume":"23","author":"S Cowan","year":"2023","unstructured":"Cowan S, Lim S, Alycia C, Pirotta S, Thomson R, Gibson-Helm M et al (2023) Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity. BMC Endocr Disord 23(1):14","journal-title":"BMC Endocr Disord"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02862-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:03:24Z","timestamp":1787040204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02862-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":416,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2862"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02862-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Flavia Prodram has served on advisory boards for Novartis.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}